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Neurotransmitters are chemicals that are secreted by neurons and relay messages to target
cells. The goal of in vivo electrochemistry is to provide a real-time view of neurotransmitters
in the extracellular space of the brain. This may be done in brain slices or the intact brain of
anesthetized animals to probe the basic functions that regulate neurotransmitter levels. In
other experiments, the measurements need to be made in the brain of behaving animals so
that correlations of neurotransmitter fluctuations and specific behaviors can be made. For the
neurotransmitter dopamine this can be accomplished today by chemical sensing of this
neurotransmitter with fast scan cyclic voltammetry (FSCV) at carbon-fiber microelectrodes.
Dopamine is an important target because it is a central player in the brain ‘reward’ system,
although its precise function is not understood. Proposed roles for dopamine in reward have
included the mediation of hedonia (pleasure)1, a messenger of incentive salience (wanting)2,
or an error signal that promotes the learning associated with goal-directed behavior3,4. These
multiple interpretations of dopaminergic function have arisen because, until recently, a real-
time view of dopamine and its actions in an awake, behaving animal was unavailable. At the
same time, new electrochemical technologies are being developed to measure other
neurotransmitter actions. Electrochemical approaches are well suited for this application
because they allow a neurotransmitter to be measured with high time resolution, enabling its
precise role in the execution of behavioral tasks to be investigated.
In this review we will describe current methods to detect neurotransmitters and monitor their
concentration dynamics within neural tissue. The requirements for these methods are quite
stringent. They need to be sufficiently selective so that the measured responses are
unequivocally due to a specific molecule. They need to be sufficiently sensitive that they can
detect these substances in the physiological range. The best established methodologies are
for dopamine, so the majority of the applications of the methods described herein will
involve this neurotransmitter. As will be seen, the goals in measuring neurotransmitter
functions are diverse. On one hand, investigators are unraveling the mechanisms that control
neurotransmitter concentrations. These studies range from examining biochemical synthesis
to metabolism. On the other hand, investigators are questioning how the neurotransmitter
interacts with its receptors and what message it conveys. Yet a third major interest is the role
of a neurotransmitter in specific behaviors. To obtain a complete view of neurotransmission
and information processing, chemical sensors need to be combined with traditional
neurochemical tools. We will illustrate this approach with some specific examples.
1. Neurotransmitters and brain function
In a recent book, the 2000 Nobel Prize winner Eric Kandel reviewed the scientific findings
that lead to our current understanding of the brain5. As this book clearly shows,
understanding the brain is a challenging research field, but significant progress is being
made through the combined input of investigators from multiple disciplines. Kandel notes
that three central principles, which emerged in the early twentieth century, form the building
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blocks for modern thinking about nerve cells and brain function. Early insights came from
the Spanish neuroanatomist, Cajal, who stained brain tissue and traced entire neurons at the
end of the 19th century, demonstrating their projections and processes. This work established
the “neuron doctrine” that has been significantly extended through modern anatomical
research involving such tools as highly specific antibodies and the electron microscope. Like
all cells, neurons have a cell body where the nucleus is located. They also have specialized
processes for input, the dendrites, and an output process, the axon. The terminals of the
axons form connections called synapses with the cell bodies and dendrites of other neurons.
These synaptic regions appear poised for communication between one neuron and another.
The next major discovery was the electrical properties of neurons. Due to multiple types of
ion channels, neurons can generate a rapid potential change at the cell body that can
propagate down the axon. This signal, termed the action potential, occurs as a result of the
encoded information from inputs to the neuron. Early pioneers in this area were Hodgkin
and Huxley. They used the squid giant axon that is sufficiently large to make intracellular
recordings of voltage and current with relative ease. Today this field has blossomed with the
advent of patch-clamp recordings that allow the activity of individual ion channels to be
observed. Furthermore, extracellular recordings of electric fields near the cell body of
individual neurons, called single-unit electrophysiology, allows action potentials to be
monitored while alert animals are executing complex behaviors6. The use of arrays of
electrodes allows entire neuronal circuits to be monitored7.
The third principle that guides current thinking about the brain is chemical synaptic
transmission. According to this principle, neurons communicate with each other at synapses
by secretion of chemical substances termed neurotransmitters that interact with specific
receptors, thus relaying information to downstream neurons. Evidence for this was obtained
in the early twentieth century when Loewi isolated fluid from a beating frog heart and
exposed it to another, nonbeating heart. The fluid induced beating in the second heart, so
Loewi correctly surmised that a chemical substance in the fluid must be responsible. This
later was discovered to be acetylcholine. Eccles, another pioneer in synaptic communication,
initially believed that it was electrical in nature, but later was convinced of the chemical
theory. He teamed up with Jaeger, the leading expert in molecular diffusion, to understand
how released acetylcholine is transported to its target8. Since these initial discoveries, a
number of molecules have been identified as neurotransmitters. The majority are stored in
vesicles situated at nerve terminals. Action potentials cause Ca2+ channels to open and the
resulting Ca2+ influx triggers the fusion of these vesicles with the neuronal membrane, a
process termed exocytosis. Exocytosis results in release of a packet of neurotransmitters into
the synapse that can then diffuse and bind to specific receptors. The receptors may be
coupled to ion channels or to a second messenger system that catalyzes a cascade of
chemical steps in the target cell triggered by the neurotransmitter binding.
At a fundamental level, electrochemistry has contributed significantly to one of the central
aspects of the chemical communication theory, exocytosis. Exocytosis was proposed as a
primary secretory mechanism in the 1960’s9. However, direct chemical evidence for this
process did not become available until the 1990’s. The initial electrochemical experiments
were done with chromaffin cells, which are cells from the adrenal gland that serve a
neuroendocrine function. These cells had been shown by electron microscopy to contain
vesicles and subcellular fractionation techniques had demonstrated that the catecholamine
chemical messengers, epinephrine and norepinephrine, were concentrated within these
vesicles10. We reasoned that exocytosis should cause a sharp concentration spike of
catecholamines to appear on a small region of the cell surface, whereas any other secretory
process would cause a continuous appearance at the surface of the electrode. To measure
secretion, a carbon fiber electrode was placed adjacent to the cell with an applied potential
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sufficient to oxidize catecholamines. When the cell was stimulated to begin secretion, sharp
current spikes arising from oxidation of the secreted substances were observed, the expected
result for exocytosis11. This experiment has been extended to neurons12–14, confirming the
exocytotic hypothesis as a primary means of neurosecretion. Today, these types of
experiments are providing dynamic information concerning the primary biochemical steps in
exocytosis15.
While the understanding of chemical neurotransmission has advanced dramatically since the
discoveries of Loewi due to a wide number of experimental approaches, this central
principle of the brain is not as well developed as the neuron doctrine and the understanding
of the electrical processes of the brain. A major impediment to understanding
neurotransmitter actions was the lack of ways to observe it in real time. As will be
described, observing dopamine changes in real time is now possible in an awake, behaving
animal, allowing correlations to be made between animal behavioral states and a specific
neurotransmitter action. The rapid development of sensors for other neurotransmitters will
likely enable a much fuller picture of animal behavior and its control by chemical substances
in the brain.
2. Non-electrochemical techniques to measure neurotransmitters within the
brain
Directly assessing chemical communication between neurons in the brain of behaving
animals is a long-standing goal. The most widely used approach is microdialysis, but
spectroscopic techniques and in vivo voltammetry also provide useful information.
2.1. Microdialysis
A recent review by Kennedy and colleagues16 reports that there are more than 9000
publications using microdialysis. In microdialysis, a perfusion fluid is pumped within a
dialysis membrane implanted in the brain region of interest. Small molecules can exchange
across the membrane and the interior fluid (termed the dialysate) is removed for external
analysis. The microdialysis method has several advantages for measurement of brain
extracellular neurotransmitters. First, it can be implemented quite easily to study a variety of
neurotransmitters. Second, the chemical resolution is very good because the dialysate, which
is removed from the brain, can be analyzed with a variety of techniques. Catecholamines
and other easily oxidized molecules have often been quantitated by liquid chromatography
with electrochemical detection, whereas amino acid neurotransmitters normally are
derivatized with a fluorophore or electrophore before separation and detection.
However, there are significant problems with the technique. Microdialysis was originally
thought to measure absolute concentrations of species in the extracellular fluid when used
with the “no net flux” procedure17 or with very slow perfusion rates18. These approaches
have been questioned because the “no net flux” equilibrium position also includes a balance
between the rate of the uptake and diffusion of neurochemicals through damaged tissue near
the probe19. When mathematical modeling includes a term to account for transport through
the damaged region, estimates of the extracellular neurotransmitter concentrations are
elevated considerably20,21. Tissue damage upon insertion of a microdialysis probe is likely
because its size (typically > 200 µm in diameter) is large compared to that of nerve terminals
(~ 1 µm). Histological studies have shown that brain tissue can be perturbed for over 1 mm
from the implantation site22. Despite this drawback, neurotransmitter concentrations change
in predictable ways with a variety of manipulations, demonstrating that information obtained
with this technique does provide insights into neuronal processes16.
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Most microdialysis experiments are done with a flow rate of 1 µL/min and this typically
restricts sampling to 10 min intervals so that sufficient dialysate is collected for handling
and analysis. This flow rate is ideal to examine the effects of pharmacological agents on
neurotransmitter levels since their transit into the brain may be slow and their effects long
lasting. However, to evaluate the role of neurotransmitters on behavioral events, more rapid
sampling is required. This is because neuronal action potentials underlying behavioral
actions occur on a millisecond time-scale, and the neurochemistry accompanying this
activity is likely to change on the same time scale. Using traditional approaches, very rapid
(down to 1 min) collection of samples has been accomplished in a few experiments23–25. An
alternate approach has been to couple the analytical methodology directly to the outlet of the
microdialysis cannula. Using this approach, Kennedy and colleagues have achieved 14-s
temporal resolution during conditioned fear experiments with microdialysis26. Extracellular
glutamate and γ-aminobutyric acid (GABA) were rapidly increased in response to a foot
shock while other putative amino acid neurotransmitters did not change. Recent advances in
microdialysis sampling and detection will be discussed further in Section 11.
2.2. Spectroscopic approaches
Spectroscopic techniques are noninvasive and can provide spatially resolved maps of
neuronal activity from the intact brain. As such, they are well suited for analysis in primates
including humans. Two methods predominate today, fMRI and PET, and they both provide
an indirect view of neurochemical activity. Positron emission tomography (PET) requires
synthesis and administration of chemical agents that emit positrons. These are usually
agonists (activators) or antagonists (inhibitors) of receptors for the neurochemical of
interest. Their displacement through competition with the endogenous ligand provides
insights into the brain regions that are involved in various behaviors such as addiction27.
Functional magnetic imaging (fMRI) takes advantage of hydrogen spins and can provide
resolution in human subjects of approximately 4 mm. In fMRI, researchers use the blood
oxygen-level-dependent signal to indicate neuronal activity in a particular region. The
hydrogen spins are affected by the degree of oxygen occupancy of hemoglobin because this
alters the local magnetic field. This technique has been used to provide strong evidence that
dopamine-containing regions become activated during reward-associated behaviors in
neuroeconomics28. Indeed, the images clearly indicate that the nucleus accumbens, a
structure with many dopamine terminals, becomes activated during anticipation of reward
(Figure 1). However, assigning the specific neurotransmitters involved in the activation
requires the use of pharmacological agents.
3. In vivo voltammetry
In vivo electrochemistry provides another route for sampling neurotransmitters in the brain.
Several neurotransmitters including dopamine, norepinephrine, epinephrine, serotonin and
histamine are easily oxidized and thus can be detected with voltammetric experiments. The
advantages of this approach are that the dimensions of the electrode can be quite small and
the measurements can have high temporal resolution. Carbon-fiber microelectrodes, which
have a diameter of 5 µm, are the most common sensors used in this application (Figure 2).
They are encased in a pulled glass capillary with 25 to 100 µm of the fiber protruding from
the glass. The small size suggests that they will cause little tissue damage and this has been
confirmed to be the case after acute implantation29. The location of the tip cannot be found
by histological examination at the light microscopy level, although electron microscopy
reveals some damage within 1–2 µm of the implantation site.
The original in vivo electrochemical experiments searching for neurotransmitters were
conducted by Adams and colleagues. In their first report ascorbate was identified as a major
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interference30. Indeed, the question of selectivity has been a major impediment to the
widespread use of the voltammetric approach.
3.1. Electrochemical properties of neurotransmitters
With respect to electrochemical detection, neurotransmitters can be separated into three
different categories.31 The first category of neurotransmitters consists of the
electrochemically active compounds such as the tyrosine derivatives dopamine,
norepinephrine, and epinephrine. Many of their metabolites are also electroactive, such as
3,4 dihydroxyphenylacetic acid (DOPAC), homovanilic acid, 3-methoxytyramine, or 3,4-
dihydroxyphenylalanine (L-DOPA). The neuroactive tryptophan derivatives are also
electroactive and include 5-hydroxytryptamine (serotonin) and its precursors or metabolites
like 5-hydroxyindolacetic acid, 5-hydroxyindoletryptophan or melatonin. Other electroactive
neurotransmitters are histamine and adenosine. All of these compounds can be directly
detected by electrochemical oxidation of the molecule. Furthermore, other electroactive
substances in the brain such as ascorbic acid, uric acid, nitric oxide, molecular oxygen, or
hydrogen peroxide are also readily detectable by electrochemical methods.
The second group of neurotransmitters is not inherently electroactive; thus, these
compounds cannot be detected by traditional electroanalytical methods. However, those that
can be oxidized by an enzymatic reaction can be measured electrochemically by coupling
the enzyme reaction with electrochemical detection. Some of the neurotransmitters in this
category are amino acid transmitters such as glutamate and GABA, as well as acetylcholine
and its precursor choline. Glucose and lactate, compounds important in energy production in
the brain, have also been detected with this indirect electrochemical approach.
Neuropeptides and some amino acid neurotransmitters form the third group of
neurotransmitters. These neurotransmitters and neuromodulators cannot be detected directly
in the brain with electrochemical biosensors at this time. The most prominent members of
this group are some of the amino acid transmitters like glycine as well as the large group of
neuroactive peptides. However, neuropeptides with electrochemically active groups such as
tyrosine, tryptophan, methionine and cysteine residues can be detected electrochemically,
although this is best done after their removal from the brain and separation on a
chromatographic column. Microdialysis probes are typically used for the sampling of these
molecules. Detection can be done with a variety of methods such as ultraviolet absorbance,
fluorescence, electrochemistry or radioactive detection32. Soft ionization techniques in mass
spectrometry are also employed in discovering and analyzing neuropeptides33. Particularly
promising in this regard is the use of capillary liquid chromatography interfaced with
tandem mass spectrometry34. Using microdialysis samples isolated from the anesthetized rat
striatum, peptide samples were introduced by electrospray into the mass spectrometer.
Samples were obtained before and after depolarization of the tissue with high K+.
Comparison of these samples revealed a total of 29 peptide sequences from 6 different
protein precursors. Of these, 25 had not previously been identified. Several of these peptides
were found to increase neuroactive amino acids when they were infused back into the brain.
In another study, a novel neuropeptide has been isolated and sequenced from a ganglion in
the crab with capillary liquid chromatography and electrospray ionization mass
spectrometry35. The peptide was then applied to the ganglion and it was found to alter the
electrophysiological properties
3.2. Electroactive neurotransmitters
Catecholamine neurotransmitters are well suited for electrochemical detection because the
potential required for their oxidation is well within the potential limits for carbon and metal
electrodes in physiological buffer36. True physiological buffers are chemically complex, but
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they can be mimicked by an aqueous solution containing 150 mM NaCl buffered to pH 7.4
with a relatively low concentration of TRIS (~15 mM trishydroxymethylaminomethane).
Catecholamines are derived in a biosynthetic pathway from tyrosine37. The rate limiting step
in the synthesis is the hydroxylation of tyrosine to L-DOPA with tyrosine hydroxylase.
Dopamine is formed by the decarboxylation of L-DOPA. The major metabolites of dopamine
are produced by reaction with monoamine oxidase and catechol-O-methyltransferase. These
metabolites are DOPAC, homovanilic acid, and 3-methoxytyramine. Norepinephrine is
formed after transfer of a hydroxyl group onto the β-position of the side chain via dopamine-
β-hydroxylase. The amine of norepinephrine can be methylated by phenylethanolamine-N-
methyltransferase to form epinephrine. The action of monoamine oxidase on norepinephrine
mainly produces vanilylmandeleic acid and 3-methoxy-4-hydroxy-phenlethyleneglycol. As
can be seen in Table 1, all of these compounds show similar 2-electron oxidation reactions
with similar peak potentials at physiological pH. For this reason it is difficult to distinguish
different catecholamines and their metabolites simply on the basis of their capacity for
oxidation. Furthermore, many of these compounds undergo secondary reactions after the
initial electron transfers. The methoxylated derivatives are oxidized at more positive
potentials than the catecholamines; however, the oxidation product loses methanol and
forms the o-quinone of the corresponding catecholamine. In the case of 3-methoxytyramine
oxidation, dopamine-o-quinone is formed, while the oxidation of HVA leads to the
formation of the oxidized form of DOPAC.
Another example for a secondary reaction is the intracyclization reaction of the oxidized
hydroquinone form of catecholamines38–40.
(1)
(2)
The 5,6 dihydroxyindoline product can undergo redox-reactions itself to an aminochrome
(reaction (2)). However, in the case of dopamine the rate constant for the formation reaction
is very slow, on the order of k = 0.1 s−1 at physiological pH. Thus, the effect of these
reactions can be outrun by using fast-scan methods or measuring quickly after a potential
step. The formation of the aminochrome product can be used to distinguish norepinephrine
and epinephrine electrochemically since the rate of cyclization is faster for epinephrine41. In
addition to this, the secondary-amine side chain of epinephrine can be oxidized at very
positive potentials whereas the primary-amine side chain of norepinephrine cannot42.
The other important group of electrochemically detectable neurotransmitter and metabolites
are the tryptophan derivatives including serotonin (5-hydroxytryptamine). During
biosynthesis tryptophan is converted by tryptophan hydroxylase to 5-hydroxytryptophan,
which then forms serotonin after decarboxylation. Metabolism of serotonin is primarily by
monoamine oxidase followed by an aldehyde dehydrogenase that leads to 5-hydroxyindole
acetic acid. A more minor pathway is metabolism of serotonin to form 5-
hydroxytryptophenol. Tryptophan derivatives can also be oxidized and electrochemically
detected in a two electron process with similar standard potentials as catecholamines. After
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oxidation many different secondary reactions have been observed43. The reaction pathway is
quite complicated and involves the dimerization of serotonin, as well as, after addition of
water, formation of tryptamine 4–5 dione.
Histamine and adenosine are other oxidizable neurotransmitters, but to date neither has been
directly detected with electrochemical methods in the brain. Histamine secretion from
isolated mast cells has been detected electrochemically44. Histamine is synthesized from
histidine via decarboxylation and has multiple metabolic products, such as
imidazoleacetaldehyde and imidazolacetic acid. Recent research has shown that adenosine
can be detected by FSCV45–48. Adenosine appears to undergo a 3-step oxidation, of which
the first two steps lead to a distinct voltammogram which can be differentiated from other
interferences (see Table 1).
3.3. Electroactive substances that interfere with neurotransmitter detection
The main electroactive interference for electrochemical measurements in the extracellular
fluid of the brain is ascorbic acid. The ascorbic acid concentration in the extracellular fluid
of the brain is approximately 0.5 mM, which is 104 –106 times higher than the
concentrations of catecholamines49,50. Early amperometric measurements showed that the
oxidation of ascorbic acid was the main signal recorded in the brain30,51. However, the
electron transfer kinetics for the oxidation of ascorbic acid at carbon are very sensitive to the
conditions of the electrode surface. Electrooxidation of carbon at very high potentials (~3.0
V) causes an acceleration of electron transfer rates so that the ascorbate oxidation peak
occurs near its thermodynamically anticipated value. Using such treatments, Gonon and
coworkers were able to show that ascorbate changed in concentration following
pharmacological treatments expected to affect catecholamines52,53. This established that
brain sensors for dopamine had to be able to distinguish the two molecules. This is
accomplished in fast scan methods at untreated carbon electrodes because the oxidation of
ascorbate shifts to more positive potentials as a result of slow electron-transfer kinetics,
distinguishing the ascorbate signal from other compounds54,55. Alternatively, electrode
modification with selective membranes can reject ascorbate from the electrode
surface50,56,57.
Besides direct electrochemical interference, ascorbic acid can contribute indirectly to the
measured signal. Ascorbate functions as the major antioxidant in the body. Thus, even when
it is rendered inactive at the electrode surface, it can play a role during the electrochemical
detection. For example, after the oxidation of dopamine, dopamine-o-quinone is reduced by
ascorbate, regenerating dopamine. This catalytic reaction by ascorbic acid provides more
dopamine for electrooxidation with the net result that the electrochemical current is
proportional to both dopamine and ascorbate58.
3.4. Electrochemical detection of neuromodulators
Recently it has been shown that hydrogen peroxide plays an important role in brain
signaling and neurotransmitter regulation59,60. Hydrogen peroxide can be detected directly
by electrochemical methods such as amperometry61. Oxygen levels in the brain are also
often determined with microelectrodes62–65. For the measurement of oxygenation of brain
tissue, electrochemical methods are an alternative approach to blood oxygen-level-
dependent fMRI measurements that monitor the oxygen dissociation from hemoglobin66.
Although electrochemical oxygen measurements have a much better spatial and temporal
resolution than fMRI techniques, many studies use fMRI techniques because of the non-
invasive nature and the global spatial view that it provides. In addition, amperometric
detection of hydrogen peroxide or oxygen is the basis for enzyme based electrodes that are
discussed further later in Section 6.
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Nitric oxide (NO), which is synthesized from arginine, has been shown to act in the central
nervous system as a secondary messenger and as a mediator in the cardiovascular
system37,67,68. When measuring NO electrochemically, electrodes with coatings or
membranes that are specific to NO are typically used. A description of these coatings can be
found later in this review (Section 4.3).
4. Voltammetric electrodes for neurotransmitter detection
The basis for electrochemical detection of neurotransmitters in vivo stemmed from the
development of microelectrodes (electrodes with dimensions in micrometer range) several
decades ago69. It was recognized early on that the small size, which minimizes tissue
damage, also results in electrodes with a low time constant that are capable of high speed
measurements. In addition, the small size minimizes distortion caused by ohmic drop.
4.1. Carbon electrodes
Early microelectrodes for voltammetric recordings in the central nervous system were
constructed from carbon paste70–72. The carbon paste was prepared by mixing carbon
powder with either Nujol or silicone oil73 and then packed into the end of Teflon insulated
metal microwires, resulting in disk electrodes with diameters between 100 and 300 µm.
Glass capillaries can also be filled with carbon paste. Epoxy resin is often added to the
carbon paste, producing a more rigid electrode after curing74,75. Carbon paste electrodes
have been reported to be stable over several months for in vivo applications. However, the
relatively large size of carbon-paste electrodes limits the applications to larger brain regions.
In addition, the larger size results in more tissue damage upon implantation in the brain in
comparison to smaller sized electrodes.
Smaller carbon electrodes can be made from carbon fibers76,77. Carbon fibers can be as
large as 30 µm in diameter, but the majority of fibers range between 5–15 µm78. Carbon
fibers are prepared from the pyrolysis of either petroleum pitch or polyacrylonitrile and
undergo thermal processing similar to glassy carbon. To make an electrode, the carbon fiber
is inserted into a glass capillary, pulled with a pipette puller, and cut to obtain a cylindrical
electrode or polished for disk electrodes. To form a well insulated seal between the carbon
fiber and the glass sheath, epoxy resin is allowed to creep between the fiber and the glass
and then cured79. Carbon-fiber microelectrodes constructed in this way cause minimal
damage to the surrounding tissue29 when inserted into the brain because the dimensions of
the whole electrode including the surrounding insulation are in the lower micrometer range.
Similar approaches can be used to insulate microscopic gold and platinum wires for
microelectrodes.
4.2. Electrochemical properties of microelectrodes
The electrochemical properties of carbon electrodes depend on the oxidation state of carbon-
containing functional groups of the surface. It has been proposed that surface carbonyl-and
hydroxyl-groups can catalyze electron transfer for inner-sphere reactions at the electrode
surface80. Furthermore, overoxidation of carbon electrode surfaces has been shown to
increase the sensitivity to positively charged analytes81, due in part to increased adsorption
of cations to the carbon surface82. An increase in sensitivity of 5- to 7-fold has been
observed in vitro for dopamine when using FSCV at overoxidized carbon fibers. However,
overoxidized electrodes show a slower time response and lower selectivity than electrodes
which have not been exposed to high oxidative potentials. In early studies overoxidation was
accomplished by repetitive excursions to + 3.0 V versus Ag/AgCl at 70 Hz52,53. Electrodes
treated this way showed higher sensitivity for catecholamines, and much faster electron-
transfer kinetics for ascorbate. However, in addition to increasing the amount of surface
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oxides, this surface treatment seems to drastically increase the surface area of the
electrode83. In modern applications, the electrode is rarely taken to potentials more positive
than +1.4 V versus Ag/AgCl.
Carbon microelectrodes are well suited for direct electrochemical detection of
neurotransmitters in the electroactive category for several reasons. In addition to the
relatively easy and cost-effective construction, carbon electrodes show very little bio-fouling
during in vivo applications, in contrast to metal electrodes that have to be further coated to
reduce bio-fouling. Fouling of the electrode surface has a deleterious impact on electron-
transfer kinetics, which can and that can distort peaks in cyclic voltammetry. Furthermore, a
larger potential range can be applied to carbon electrodes than to metal electrodes which
readily undergo electro-oxidation.
Gold and platinum microelectrodes have been used to directly detect catecholamines in
vitro84–87. However, because of the relatively small potential window compared to carbon
electrodes and problems with bio-fouling, metal electrodes are not commonly used for direct
electrochemical detection of electroactive neurotransmitters. Platinum and gold electrodes
are commonly used for enzyme electrodes to detect neurotransmitters with enzymatic
catalysts in vivo. Micropatterning of gold and platinum onto substrates allows metal
microelectrodes to be fabricated as arrays with multiple electrode sites88–90. However, in all
of these applications, the noble metals are typically protected with a polymer film to prevent
bio-fouling. At gold electrodes, thiol adsorption is a common problem. In brain tissue,
glutathione is present at relatively high concentrations and will rapidly passivate an
electrode.
When using a 3-electrode potentiostat for electrochemical measurements in the brain, the
auxiliary electrode is most commonly a stainless steel electrode which is brought in contact
with the surface of the brain at a convenient location. When using microelectrodes a 2-
electrode setup is often used, consisting only of a working electrode and a reference
electrode. Two electrode systems are preferred because the currents are sufficiently small
that the polarization of the reference electrode is negligible. Also, with an extracellular NaCl
concentration of ~ 150 mM, the electrolyte concentration is high enough to minimize the
solution resistance. Reference electrodes are normally a small-diameter silver wire, which
has been anodized in hydrochloric acid to form a silver chloride layer on the surface of the
wire and implanted directly into the brain tissue91.
4.3. Surface modified electrodes
Different coatings have been applied to electrode surfaces to overcome some of the
limitations of the electrochemical detection schemes. Surface coatings are widely employed
to increase sensitivity and selectivity for certain analytes as well as to prevent surface
fouling. Nafion, a perfluorinated cation-exchange polymer, is a commonly used electrode
coating57 for catecholamine detection because the biogenic amines are positively charged at
physiological pH. Nafion can be applied by dip coating the electrode in a suspension of
2.5% Nafion in isopropanol and allowing the solvent to evaporate, leaving a Nafion film.
The strong hydrophobicity of the Nafion layer minimizes surface fouling while sulfonate
groups within the Nafion network promote accumulation of cations and reject anions. An
alternate approach is the deposition of an overoxidized polypyrrole-film on the electrode
surface92–95. These films exhibit similar properties to those described for Nafion films.
However, both coatings are noncovalently attached layers that have finite thickness. The
thickness means that there is a finite time required for molecules to diffuse through the
coating, which increases the response time of the electrode. To remove this component,
deconvolution methods have to be used to extract the real time response curves at these
modified electrodes96. Carbon paste electrodes can be modified by mixing stearic acid into
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the carbon paste97–99. These electrodes have been reported to have a high sensitivity and
selectivity for dopamine over other electrochemical interferences present in the brain like
ascorbic acid and DOPAC, although the mechanism is not understood. More recently,
carbon-fiber microelectrodes have been modified by covalent attachment of molecules via
diazonuim salt reduction. Most commonly, the electrodes are modified with anionic
functional groups like carboxyphenyl100, phenylacetate101, or sulfobenzene102. Electrodes
modified in this way show a higher sensitivity and selectivity to cationic analytes such as
catecholamines over anionic analytes like ascorbic acid without slowing down the time
response of the detection.
Nitric oxide can be detected via direct oxidation according to the reaction scheme in Table
1. Different surface coatings have been used to create an electrode that is selectively
sensitive to nitric oxide. These coatings minimize interferences from hydrogen peroxide,
O2−, and derivatives of nitric oxide such as ONOO− and NO2−, which is the main
interference for these measurements. Elimination of these interferences is the biggest
challenge in creating a nitric oxide sensor. Early nitric oxide sensing electrodes used a
Clark-type electrode with chloroprene rubber as the NO selective membrane103. Carbon
fiber microelectrodes coated with o-phenylenediamine and Nafion104 also showed a very
high selectivity for nitric oxide. Recent research showed that it is possible to detect the
interferences H2O2, ONOO−, NO, and NO2− that can be distinguished by their different
oxidation potentials in a potential step experiment105. Platinum-iridium electrodes coated
with a nitrocellulose/pyroxylin layer were used to measure NO concentrations in various
biological applications106. Recently, NO concentrations have been electrochemically
detected in tumor-bearing mice with a Nafion/o-phenyldiamine coating on a platinum-
iridium microelectrode107. Other approaches include electrodes modified with layers of
Nafion and nickel tetrasulfonate phthalocyanine tetrasodium salt108 or electrodes coated
with silicone based xerogels which are doped with methoxysilanes109. However, these
approaches have not yet been tested in vivo.
5. Electrochemical techniques for neurotransmitter detection
Different electrochemical techniques are used to directly detect the electroactive
neurotransmitters. The most common techniques are constant-potential amperometry,
chronoamperometry, differential pulse voltammetry and FSCV.
5.1. Amperometry
In constant-potential amperometry the working electrode is held at a DC potential sufficient
to oxidize or reduce the compound of interest at the electrode surface. The presence of an
electroactive species that undergoes electron transfer at this potential generates a measurable
current. The integral of the current with respect to time (charge, Q) is directly proportional
to the amount (m) of the species electrolyzed at the electrode surface by Faraday’s law (Q =
nFm, where n is the number of electrons in the redox step, and F is Faraday’s constant).
With constant-potential amperometry very high time resolution can be achieved. With a
sampling rate in the kHz range, constant-potential amperometry can resolve signals on the
sub-millisecond time scale. Adsorption of reactants at electrodes is not a concern with
constant-potential amperometry because species are electrolyzed immediately upon contact
with the electrode. For this reason adsorption processes do not slow down the response to
concentration changes of the analyte as occurs with voltammetric techniques, although
sensitivity tends to be lower. Collectively, these properties make constant-potential
amperometry a useful technique to measure vesicular neurotransmitter release from single
cells11,110–112. Studies using amperometry have allowed for attomole to zeptomole
quantities of neurotransmitter secreted from single cells to be detected14,113–115.
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Although amperometry can be used to determine amounts secreted, it is not particularly
useful for determining concentrations. This is because the dimensions and shape of the
diffusion layer must be designed to be identical during calibration and in the preparation of
interest. Despite this, amperometry has been successfully used to study catecholamine
concentrations in the brain and in brain slices116,117. It has been shown that the addition of
ascorbic acid provides a way to obtain accurate in vitro calibrations for catecholamine
detection118. Recall that the catalytic reaction of ascorbate with dopamine-o-quinone
regenerates dopamine. If the reaction occurs at a similar rate in the calibration solution and
in the brain preparation, the diffusion layer dimensions will be the same in both
environments, and the calibration factor obtained in vitro will approximate its value in vivo.
However, constant potential amperometry is inherently non-selective. All electroactive
compounds that oxidize or reduce at the holding potential will produce a faradaic current
detected at the electrode. Therefore it is important to use independent measures to identify
the molecules responsible for the detected currents to confirm amperometric traces.
5.2. Chronoamperometry
In chronoamperometry the applied potential is instantaneously stepped from an initial
potential at which no electrochemical reaction is occurring to a potential sufficient to oxidize
or reduce the molecule of interest. The potential is then stepped back to the initial holding
potential in a rectangular fashion. The current observed during the initial potential step is
proportional to the concentration of the electroactive species present and decays with the
inverse of the square root of time if the current is governed by diffusion. Traditionally the
current is measured at a fixed time into the potential step and this is used to calculate the
concentration of the analyte. On the step back to the initial potential, the species that were
originally oxidized are reduced. From the ratio of the currents measured on the reverse and
forward potential step, information about the stability of the oxidized species can be made.
This feature provides chronoamperometry with somewhat greater selectivity than constant-
potential amperometry. Chronoamperometry has often been used to measure
neurotransmitter concentrations, especially serotonin119,120 and dopamine121–123, in the
extracellular fluid of the brain in real time. However, because of its limited chemical
selectivity, it is most often used to measure neurotransmitter dynamics following injection of
the authentic substance or an agent that immediately causes release.
5.3. Differential pulse voltammetry
An electrochemical method used in many early reports of in vivo neurotransmitter
measurements is differential-pulse voltammetry. Differential-pulse voltammetry is a
combination of linear sweep voltammetry with square wave techniques. The applied signal
is a small amplitude square wave (~25mV) at a constant frequency superimposed on a slow
linear potential ramp. The current is measured both shortly before each square wave is
applied and again shortly before each pulse ends. The difference between these currents is
plotted versus the potential of the linear sweep. The differential currents give a symmetric
voltammetric peak whose amplitude is proportional to the concentration of the analyte. In
contrast to amperometric methods, it is possible with differential-pulse voltammetry to
simultaneously measure different analytes as long as the oxidation potentials of these
compounds are separated by more than 100 mV32. Differential-pulse voltammetry has been
used in the past for in vivo neurotransmitter detection of catecholamines52,124 and
serotonin125, as well as oxygen63. However, differential-pulse voltammetry shows a
relatively poor time resolution as one scan takes longer than 30 s, whereas we now know
that neurotransmitter fluctuations occur on a subsecond time scale.
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5.4. Fast scan cyclic voltammetry
Fast scan cyclic voltammetry (FSCV) is an electrochemical technique that provides a much
higher temporal resolution than differential-pulse voltammetry but still shows high
selectivity126. In FSCV the potential applied to the electrode is cycled at scan rates faster
than 100 V/s in a triangular fashion (Figure 2). The voltage limits are chosen so that the
reduction and oxidation of the analyte of interest lies within this potential window. At high
scan rates the majority of the current detected at the working electrode is a non-faradaic
current due to charging of the double layer and, depending on the material of the electrode
used, redox processes at the electrode surface80,127. Typically this large background current
is subtracted128 so that the smaller changes in faradaic currents due to redox processes of
electroactive species can be monitored. Because the background current is only stable for a
brief time, FSCV is typically only used to observe concentration changes over the time
course of a minute. Furthermore, because of the differential nature of the technique it is not
possible to measure basal concentrations of electroactive species. FSCV has been shown to
be very useful for the detection of catecholamine fluctuations in vivo because of the high
sensitivity and selectivity129. Typically with FSCV a time resolution of 100 ms is achieved
by applying the waveform for 10 ms and repeating it at 100 ms intervals. Since FSCV is a
potential sweep technique, analytes with different oxidation potentials can be distinguished
by their peak positions for the oxidation and the reduction as well as by their peak shape130.
In the intervals between each scan, where the electrode is typically held at a negative
potential, catecholamines have been shown to adsorb to the electrode surface131. This
adsorption causes a preconcentration of the catecholamine at the surface before each
voltammetric scan. Anionic compounds do not show this preconcentration process; thus, this
procedure enhances selectivity for cations. A further increase in selectivity is achieved by
the application of high scan rates itself. Compounds with slower electron transfer rates like
ascorbate can be distinguished very easily from biogenic amines at high scan rates because
the oxidation of ascorbate is drawn out to higher potentials54,55.
In our laboratory, a set of background-subtracted cyclic voltammograms is collected and
examined using a color representation of the current with acquisition time as the abscissa
and applied voltage as the ordinate132. In this way many cyclic voltammograms can be
viewed simultaneously to look for the presence of specific substances and to discriminate
against electrical noise. We have taken two approaches to statistically verify identification.
One procedure is to obtain cyclic voltammograms of authentic candidates suspected to be a
component and evaluate their correlation of shape with the species detected in vivo133. A
more recent approach we have adopted is to build a calibration set of suspected candidates
and then evaluate the contributions of different species with principal component
regression130. In this procedure, the calibration set of cyclic voltammograms obtained at
different concentrations is evaluated to find the eigenvectors (principal components) that
describe the data134. Only a few are needed, and thus the dimensionality of the 1000 point
cyclic voltammograms can be reduced considerably. The principal eigenvector captures the
maximum variation in the calibration set. The second eigenvector captures additional
variance not described by the first eigenvector. This process is continued until all the
relevant information is captured. Next a regression matrix is calculated that provides the
necessary scaling factors for the retained principal components. The cyclic voltammograms
obtained during the experimental situation are then resolved into components at their
respective concentrations using the eigenvectors and the regression matrix. This procedure
results in separate traces for each chemical species used in the calibration set and an error
signal, the residual. We accept the results of the analysis as long as the residual remains
smaller than the level set by the 95% confidence limit135. If a species is present in the
experimental results but not in the calibration set, it will be included in the residual along
with noise and other interferences.
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5.5. pH electrodes for in vivo use
Fluctuations in pH in discrete brain regions have been shown to follow electrical stimulation
of dopamine neurons and seem to be an indirect measure of metabolism coupled to blood
vessel dilation and oxygenation of the tissue64. Microelectrodes to measure pH in the brain
have been developed with different approaches. One approach utilizes double barreled, thin
wall capillary glass136–138. The pH sensitive barrel is filled with a hydrogen ionophore
cocktail to provide a liquid pH sensitive junction. Theshydrophobic cocktail functions in a
way that is analogous to the glass membrane of a traditional glass electrode. The second
barrel is traditionally the reference barrel and is filled with a buffer solution at physiological
pH. The electrodes are used in a potentiometric mode with the voltage difference between
the two electrodes measured. Electrodes produced in this fashion have been shown to
resolve at least 0.001 pH units in a millisecond time scale136.
A different approach uses metal microelectrodes as micro-pH sensors. Most commonly
iridium-oxide has been used as the electrode material. Iridium oxide electrodes show a linear
sensitivity over a pH range of 2 – 10, exhibit low susceptibility to other cationic
interferences, and seem to function under in vivo conditions139,140. Anhydrous iridium
oxides have Nernstian responses to pH changes that originate from the reactions between the
+III and the +IV states of iriduim:
(3)
(4)
Because the redox potential for both reactions (3) and (4) is dependent on the pH of the
solution, the pH-measurement can be made potentiometrically versus a Ag/AgCl reference
electrode. Recent research has shown that iridium-oxide pH sensors can be patterned in a
microelectrode array to allow simultaneous recording at multiple sites141.
In vivo pH changes can also be measured with background subtracted FSCV at carbon
electrodes64,142,143. Carbon-fiber electrodes respond to pH changes because one of the
contributions to the background current is electrolysis of oxide groups on the electrode
surface. The electrolysis is pH dependent, and a differential signal is observed when the pH
changes as a consequence of the background subtraction procedure. The amplitude of this
change is directly proportional to the amplitude of the pH change.
6. Enzyme electrodes for detection of neurotransmitters
Considerable research has been conducted over the last couple of decades to design
electrochemical sensors for molecules that are not electroactive. These sensors rely on the
principle that during the oxidation of an analyte by an enzymatic reaction an electroactive
species is formed that can be detected at the electrode surface (Figure 3). With this
technique electrochemical sensors that measure glucose and lactate concentrations in the
brain have been constructed to study brain metabolism. The design features of these
electrodes have been adapted to detect glutamate, choline, acetylcholine, GABA and
adenosine144,145. Detection with enzyme electrodes normally utilizes amperometric
detection. Thus, it is important to construct electrodes with selective membranes to
minimize interfering signals146.
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6.1. Design principles of electrodes for metabolic substrates
An important driving force for the development of enzyme electrodes was the need for a
reliable glucose sensor for blood measurements in diabetic patients. The first enzyme-based
glucose-sensing electrodes were developed in the 1960’s147,148 by immobilizing glucose
oxidase embedded in a gel-matrix on a Clark-type oxygen electrode. The enzymatic reaction
turns glucose into gluconic acid with consumption of oxygen.
(5)
The configuration of the sensor depends on whether reaction (5) is monitored by measuring
hydrogen peroxide production or oxygen consumption, both of which can be detected by
their electrochemical reduction. When oxygen is measured a low reducing potential is
required for amperometric detection. This eliminates interferences because only a few
endogenous electroactive species undergo electron transfer in this potential region.
However, hydrogen peroxide detection by its oxidation is often used, although the relatively
high potential (0.6 V versus Ag/AgCl) that is applied to the electrode significantly increases
the number of interfering electron donors. Redox mediators are commonly horseradish
peroxidase coupled to an osmium complex, ferrocene, or polypyrrole149–150 to enable the
use of lower applied potentials (0 V versus Ag/AgCl). This way the interferences by
endogenous species can be minimized. However, the presence of oxygen can cause
interferences itself at a redox-mediated electrode. If the reaction of the redox-mediator with
the reduced enzyme is relatively slow compared to the reaction of the enzyme with oxygen
directly, low sensitivity will result. Therefore, mediators that react rapidly with the reduced
enzyme are desired or selective gas membranes have to be used for the construction of the
electrode.151
Miniaturized glucose sensors based on hydrogen peroxide sensing have been developed for
subcutaneous monitoring152, as well as for direct measurements in the brain153,154 to study
brain metabolism155. Lactate oxidase156–158 can also be used as the reactive enzyme to
obtain further information about brain metabolism:
(6)
A critical component for both glucose and lactate sensors is the availability of molecular
oxygen. Because of active respiration within the brain, free oxygen concentrations are lower
than 50 µM.159 Therefore, membranes over the surface of the sensor serve to restrict the flux
of analyte so that the oxygen is not completely depleted during detection. Electrochemical
glucose and lactate detectors have also been used with microdialysis probes that allow
removal of extracellular fluid for on-line, high-resolution detection outside of the
brain160,161.
6.2. Adaptation of sensor technology for neurotransmitters
The developments in the field of glucose sensors have been exploited to develop
electrochemical detectors for neurotransmitters. Glutamic acid, or glutamate, is the major
excitatory neurotransmitter in the central nervous system. It is synthesized from glutamine in
glial cells where it is converted by glutaminase into glutamate. Alternatively it is
synthesized from glucose via the Krebs cycle. Most electrochemical glutamate sensors have
been constructed from metal electrodes, most commonly platinum coated with a thin layer
of electropolymerized o-phenylenediamine162 or Nafion. These surface-coated polymers
minimize interferences, especially anionic compounds. Glutamate oxidase, the enzyme that
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breaks down glutamate in a layer of BSA and glutaraldehyde on top of the Nafion
layer89,90,163–166.
All these electrodes follow the basic electrochemical detection scheme for glutamate (7 to 9)




The first two steps of this reaction scheme occur in the outer enzyme-containing layer. The
hydrogen peroxide that is generated in reaction (8) then diffuses through the selective
membrane to the electrode surface where it gets oxidized in a two-electron process (reaction
9). Glutamate electrodes currently exhibit a detection limit of around 1 µM and a linear
range up to 200 µM for in vitro calibrations90.
The neurotransmitter acetylcholine is synthesized in vivo from choline by choline
acetyltransferase. Electrodes designed for the detection of choline are similar to those
described for glutamate detection168,169. Instead of glutamate oxidase, choline oxidase is
immobilized. The first reaction step is shown in the following reaction scheme:
(10)
Hydrogen peroxide can either be detected directly at the electrode170 as shown in reaction
(9). To monitor acetylcholine concentrations, acetylcholine esterase is added to the electrode
surface to convert acetylcholine to choline:
(11)
Choline is then oxidized according to reaction (10), which then leads to reaction (9).
Because choline is present in the brain as well as being one of the products in the reaction
cascade, it is important to have an independent measure of choline. This can be done in a
differential manner by subtracting the signal from a choline sensor from the overall signal
recorded at the actetylcholine sensitive electrode170,171. For this measurement, it is
important to carefully match the response of the two sensors to choline because the
concentration of choline in the brain can be two orders of magnitude higher than
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acetylcholine concentrations. However, in at least one documented example, a choline
sensor adsorbed enough acetylcholine esterase that it became sensitive to acetylcholine172.
Another neurotransmitter that can be detected electrochemically after an enzymatic reaction
is the inhibitory amino acid transmitter γ-aminobutyric acid (GABA). Glutamate is the
biochemical precursor for GABA. GABA is formed after α-decarboxylation of glutamate.
The bioenzymatic system used for GABA detection is comprised of the enzymes GABA-α-





The reaction for the electrochemical detection of GABA is a three-step process. The product
of the first two enzymatic reactions (12 + 13) is NADHP, which is formed from NADP+
embedded in the enzyme layer. NADHP is then re-oxidized to NADP+ after reacting with
horseradish peroxidase. The amperometric detection is based on oxygen consumption in
reaction (14). However, to date GABA electrodes have been used little for direct in vivo
applications. GABA detection is primarily conducted by separation methods after
microdialysis.
In addition to direct electrochemical detection48, purines such as ATP, ADP, and
adenosine175 have been detected in vivo with enzyme electrodes176. ATP sensors have been
constructed by combining glucose oxidase and hexokinase. The signal recorded for changes
in ATP is due to the reduction in the glucose signal via phosphorylation of glucose to




This detection scheme again utilizes the amperometric detection of hydrogen peroxide at the
electrode.
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To further eliminate interferences in the amperometric signal, self-referencing electrodes
have been developed89,90. With this electrode setup two electrodes are placed within a very
close proximity to each other by constructing the microelectrodes via photolithographic
etching. Only one of the electrodes sites is coated with the enzymatic coating, while the
other site is coated in the same manner but without addition of the enzyme. This non-
enzyme-containing electrode serves as a reference electrode that can sense all
electrochemical signals originating from interfering species. The signal is then subtracted
from the signal measured at the enzymatic electrode to obtain a signal that is purely due to
the analyte of interest. This method can be applied to all types of enzyme electrodes
described here. However, the prerequisite for this technique is that the chemical
environment is identical at each of the two electrode sites and that both electrodes have
identical sensitivities to interferences.
7. Aspects of chemical communication revealed via electrochemical
techniques
Once a sensor is constructed and a neurotransmitter of interest can be reliably detected, a
number of questions and issues can be addressed concerning the neurotransmitter. For
example, how is a particular neurotransmitter transported through the extracellular space?
What factors regulate its concentration? What is its lifetime outside of a neuron? How is it
affected by pharmacological agents? How does it interact with its receptors? These
questions are currently being addressed for dopamine. In the future, these same issues will
need to be addressed with the enzymatic sensors that allow many more neurotransmitters to
be examined.
7.1. Dopamine diffusion and uptake
Just as in a quiescent solution, diffusion plays the dominant role in the mass transport of
dopamine and other small molecules within the extracellular space of the brain.
Understanding diffusion of neurotransmitters is important because it dictates how far they
can traverse from their release site and interact with receptors. In seminal studies, Nicholson
introduced substances into the brain using iontophoresis (see section 9.2 for a discussion of
this technique), which were then detected with ion selective electrodes180.
Tetramethylammonium ion was used extensively as a probe ion because it has few specific
interactions with brain tissue and, thus, its rate of arrival at the sensing electrode was
predominantly due to diffusion. These studies showed that diffusion in the extracellular
space has two features that cause it to be different from diffusion in solution. First, dilution
is not as great as it is in solution because of the reduced volume fraction of the extracellular
fluid. Surprisingly, however, the fraction that is extracellular fluid in the brain is quite large,
approximately 20% of the total volume. Second, the rate of diffusion in the extracellular
fluid is affected by tortuosity. The presence of neurons, glia, blood vessels and other cells
make a tortuous path that effectively slows the diffusional rate. Quantitative measurements
show that diffusion coefficients have a value in the brain that is approximately one third of
their solution values as a result of the tortuosity.
In early experiments, our laboratory injected dopamine into a brain slice that was maintained
in an active metabolic state, and we attempted to monitor dopamine following its diffusion
to the electrode181. Interestingly, we were unable to detect any injected dopamine in the
caudate nucleus, a brain region in which dopamine is a neurotransmitter, but we were able to
detect it using identical methodology in a brain region that did not contain dopaminergic
nerve terminals (Figure 4). Subsequent experiments showed that the failure to see dopamine
reach the electrode in the caudate nucleus was because the dopamine transporter removed it
from the extracellular space before it could reach the electrode. This did not occur in brain
Robinson et al. Page 17













regions that lacked the transporter. In the caudate nucleus, addition of the competitive
inhibitor of the dopamine transporter, nomifensine, allowed dopamine diffusion to be
observed. These experiments established that mass transport of dopamine in the brain is
actually a competition between uptake, which removes dopamine from the extracellular
fluid, and diffusion, which dilutes its concentration.
Uptake by the dopamine transporter follows the Michaelis-Menten equation182. Thus, at
high concentrations dopamine is transported into terminals at a rate that is linear with time
and that is given by the maximum velocity, Vmax. Of all the brain regions tested in the rat,
the Vmax is largest in the caudate nucleus with a value of 4 µM/s and smallest in regions
with less transporter density. In contrast, the Km for uptake is approximately 200 nM in all
regions. This value is of interest because enzymes exhibit Km values slightly greater than the
concentrations they are expected to experience under physiological conditions. The
dominance of dopamine uptake was more recently demonstrated by monitoring the
clearance of endogenous dopamine in transgenic mice lacking the dopamine transporter.
Dopamine clearance in the transporter knock-out mice was 100 times slower than in tissue
from wild-type mice183.
A complete description of the interaction of dopamine diffusion and uptake in the brain
requires that one solve the relevant diffusion equations coupled to the Michaelis-Menten
equation to account for uptake. Nicholson has presented a numerical solution to this problem
for introduction of dopamine from a point source184. This work has shown that near the
point of delivery uptake is saturated, and the competition between Vmax and diffusion
predominates. However, at distances further from the source, the concentration of dopamine
rapidly drops as the transporter becomes unsaturated due to dilution of the initial
concentration by the combined effects of diffusion and uptake. Under these conditions, the
concentration profile resembles behavior for diffusion competing with first order kinetics
that has a rate constant given by Vmax/Km. Figure 5 (top) illustrates this with a high
concentration at 0–10 s (during application) and 0–100 µm, while thereafter concentration
drops as uptake removes dopamine from the extracellular space. The dopamine
concentration extends in both time and space when uptake is inhibited by nomifensine
(middle, a competitive uptake inhibitor) or completely absent (bottom). Cragg and Rice have
used this limiting form to model release from single nerve terminals firing alone and have
emphasized that dopamine concentrations reach very low values after a short distance
because of these competing processes185. However, it is important to note that if adjacent
nerve terminals release dopamine simultaneously the point source approximation no longer
holds. These more complex conditions have been modeled with finite difference simulations
that account for the coupling of uptake and diffusion186. The simulations reveal that
dopamine concentration is less diluted than in the case of a point source and can diffuse
farther at concentrations sufficient to interact with dopamine receptors. Nevertheless, the
diffusion distance is still only a few micrometers.
7.2. Modeling dopamine release and uptake
Release from nerve terminals is the physiological way in which dopamine enters the
extracellular fluid. Early approaches to elicit release used chemical stimulation. However, a
better approach is to take advantage of the electrical properties of neurons. Action potentials
can be evoked with brief trains of millisecond-wide pulses. The electrical stimulation
provides a distinct, time-locked stimulus that can be applied to discrete brain regions to
evoke dopamine release. Upon stimulus termination, the restoration of dopamine
concentrations to their prestimulus value can be observed. As discussed above, the lifetime
of dopamine in the extracellular space on the second time scale is clearly affected by uptake
and diffusion. Metabolism plays a role on a longer time scale187.
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We adopted this approach in the 1980’s and the resulting data were were interpreted with a
relatively simple model. If uptake by the dopamine transporter is primarily responsible for
the removal of dopamine from the extracellular kinetics, then it should follow Michaelis-
Menten kinetics as established in preparations of isolated nerve terminals. Thus, when
measured as a function of time, the disappearance of dopamine after the stimulation should
obey the following equation:
(17)
where Vmax is the maximal rate of dopamine uptake and Km is the Michaelis constant that
has been determined by independent methods to have a value of 0.2 µM188. The in vivo data
was found to follow this predicted behavior. During the stimulation, we assumed that each
each stimulus pulse in a train evoked a spatially uniform concentration change in
extracellular dopamine, and that this concentration was lowered by the transporter, again
following Michaelis-Menten kinetics189. The expected behavior during the stimulation is
therefore:
(18)
where [DA](t) is the dopamine concentration during a stimulation composed of n pulses and
that has a duration, τ. [DA]p is the concentration of dopamine evoked by each stimulus
pulse. Because the electrical stimulation forces a large population of dopamine neurons to
fire, we assumed that dopamine concentration gradients were minimal so that diffusion
could be ignored. However, the concentrations reported by the electrode were distorted by
the limited response time of the electrode, which arose from diffusion through Nafion
coatings190 or the kinetics of dopamine adsorption/desorption at uncoated electrodes131.
This model has been used extensively to characterize endogenous dopamine release and
uptake, as well as effects of pharmacological agents on these processes191. For example,
cocaine slows down the uptake portion of the observed response, consistent with its role as a
dopamine uptake inhibitor (Figure 6). Haloperidol, a neuroleptic drug used in the treatment
of schizophrenia, alters the amount of dopamine released per stimulus pulse. The model
correctly predicts that the concentration of extracellular dopamine evoked by a low (5 Hz)
frequency stimulus rapidly achieves a steady-state level during the stimulation whereas a
high frequency (60 Hz) stimulus causes the dopamine concentration to increase during the
stimulation. The latter result occurs because the rate of release greatly exceeds the rate of
uptake. In contrast, the steady-state response at low frequency stimulations is simply a
consequence of a slight imbalance in these two parameters. The model also successfully
describes norepinephrine release evoked by electrical stimulation192 as well as the dynamics
of 5-HT release193. Recently developed software allows extraction of kinetic parameters for
uptake and release using a Simplex optimization routine194.
Nevertheless, in evaluating this model it quickly became clear that it could only describe
dopamine release under a limited set of conditions. The assumption of constant dopamine
release per stimulus pulse failed with long stimulation trains. Furthermore, to achieve
reproducible amplitudes some interval of time had to occur between consecutive stimulation
trains195,196. Thus, Justice and coworkers developed a more complete model that alleviated
one of these limitations197. They recognized that dopamine is stored within two ‘pools’ of
presynaptic vesicles that have been termed the readily releasable and the reserve pools. The
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Justice model explains that the delay required between consecutive stimulation trains is
necessary to allow the reserve pool to refill the readily releasable pool. By incorporating this
reserve compartment into the model, it was able to accurately describe release and uptake
over a broader range of conditions. Recent experiments suggest that the reserve pool is
segregated from the releasable pool by the protein synapsin198,199. This vesicle-binding
protein appears to sequester vesicles away from sites where they can undergo exocytosis.
Interest in the modeling of dopamine release and uptake has recently been renewed due to
unexpected results from behavioral experiments. Rats will press a lever coupled to
instrumentation that electrically stimulates their dopamine neurons using pulse trains similar
to those used in the characterization experiments200. Apparently, the response is rewarding
because the animals will press the lever for extended periods of time, ignoring food and
water. However, the extracellular dopamine release profiles observed during these
stimulations differ from the predictions of the simple ‘Wightman’ model described above
(eqn. 18). For example, during continuous lever pressing, the evoked dopamine
concentrations decrease, eventually reaching undetectable levels. To address this issues,
Montague and colleagues201 derived a dynamic model of dopamine release that included
three independent adaptive processes. These components – a short-lasting facilitation, a
short-lasting depression, and a longer-lasting depression – fit the changing amplitude of
dopamine release events elicited by a variety of stimulus patterns in awake and anesthetized
rats (Figure 7) without the need to adjust the values of Km and Vmax for uptake. Moreover,
the mechanisms underlying each component were suggested to be well-described terminal
processes. For example, the long-lasting depression may be linked to the rate of dopamine
biosynthesis and the mobilization of vesicles in the reserve pool to the readily releasable
pool of dopamine vesicles196,202, processes described by Justice in his original model.
The short-term depression component indicated in Montague’s model operates on a similar
time scale to negative feedback from dopamine D2 autoreceptors, receptors on dopamine
nerve terminals that are responsive to dopamine203. Binding of dopamine to the
autoreceptors decreases both dopamine synthesis and release probability due to activation of
intracellular second messenger cascades. Kita and colleagues204 directly tested whether the
short-term depression component resulted from dopamine autoreceptor activation. First, the
effect of an initial stimulation train on dopamine neurons on a subsequent train was tested by
varying the delay between the two; the closer the second train followed the first, the smaller
the amplitude of the resulting dopamine release event. Consistent with earlier studies203,205,
blocking D2 autoreceptor activity with haloperidol both increased the amplitude of the
dopamine signal at the first stimulation train (revealing a tonic control of dopamine release
by D2 receptors) and increased the amplitude of the dopamine signal at the second train.
This confirmed classic autoreceptor effects to suppress dopamine release. Next, we
examined drug effects on more complex patterns of stimulation trains. Both raclopride, a D2
antagonist (inhibitor), and quinpirole, a D2 agonist (activator), modulated the initial stimulus
train in predictable ways (amplification and attenuation, respectively). However, their
effects on subsequent stimulations were more complex. While raclopride removed the short-
term depression component indicated by Montague’s model, it also removed the short-term
facilitation. Conversely, the D2 agonist quinpirole amplified both components. This
paradoxical finding that D2 receptor activation underlies both depression and facilitation of
dynamic dopamine release may be explained by a rapid desensitization process: that is,
while the initial effect of D2 activation is to decrease subsequent dopamine release, this
process quickly desensitizes, and the desensitization manifests itself as an apparent
facilitation204.
How much does our understanding of electrically stimulated release, in which many neurons
simultaneously fire, translate to insight of physiological dopamine transmission? In fact, it
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has been more useful than originally expected. First, electrophysiological recordings of
dopamine neurons in primates reveal that approximately 75% of dopamine neurons exhibit
increased firing rates at the presentation of salient stimuli206, suggesting synchronous firing
under some conditions. Moreover, electrical coupling of dopamine neurons via gap
junctions207 may promote coincidence during firing in bursts208. Finally, the validity of
models of stimulated release has been implicated by the occurrence of dopamine transients:
brief, high concentrations of dopamine that naturally occur in vivo, likely result from burst
firing of dopamine neurons, and can be pharmacologically manipulated in a manner
consistent with stimulated release.
8. Phasic dopamine transmission in vivo
In recent years, many studies have used FSCV to measure brief, local fluctuations of
dopamine occurring in vivo in rats that are freely moving and unrestrained. The transition
from measurement of dopamine signals that were electrically evoked to naturally occurring
was possible due to increased sensitivity of both electrodes and instrumentation209.
However, present studies now reveal that spontaneous transients are absent in animals
anesthetized with urethane210 and only occur in the awake state. Thus, experiments in freely
moving animals have been especially significant in that they provide a window on dynamic
dopamine chemistry that can be directly associated with learning and motivated behavior.
8.1. Measurements in freely moving rats
Taking the procedures and approaches that were used in anesthetized animals and adapting
them for freely moving rats required several developments. First, because the carbon-fiber
microelectrodes were thought likely to fail when chronically implanted, a procedure had to
be devised to insert a fresh electrode each day. Rebec and colleagues devised a
micromanipulator that could be fitted on the skull and could be used to lower the electrode
down into the brain region of interest. Their initial experiments with this approach revealed
a transient surge of dopamine when a rat was exposed to a new environment211.
In our own laboratory, we rapidly adapted this technology. In addition, surface mount
operational amplifiers were used to construct a current transducer that fit directly on the
animal’s head212. Special precautions have to be taken to eliminate noise associated with the
wires and commutator that allow the animal to freely move around the behavioral chamber.
The procedures are now well documented91, and measurements in freely moving animals
are more commonplace than they were just 10 years ago.
8.2. Basal rates of dopamine transients
The initial measurements of naturally occurring dopamine transients were made at the
presentation of highly salient stimuli to the rat, such as another rat213 (Figure 8). These
stimuli were predicted to induce synchronized burst firing of dopamine neurons that would
result in dopamine transients. However, a subsequent study revealed that dopamine
transients also occurred throughout the dorsal and ventral striatum (i.e., dopamine release
sites in the forebrain) in the absence of obvious external stimuli214. Later studies confirmed
these unexpected results. Notably, as detection limits have decreased with improved
instrumentation and technique, the observation of dopamine transients at baseline has
become more frequent and the average amplitude of these signals has decreased. Current
studies report that dopamine transients occur at > 1 min−1 in the nucleus accumbens during
baseline with a mean maximal concentration of 40 – 50 nM209, although the distribution of
the maximal concentrations suggests that even smaller fluctuations occur215.
However, discussion of average frequency rates of dopamine transients masks the dramatic
heterogeneity observed across multiple recording sites, even within the same rat. As the
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carbon fiber electrode used in these experiments is small, typically a 6 × 100 µm cylinder, it
is measuring from a finite number of dopamine release sites. Dopamine terminals are
approximately 4 µm apart in the striatum216 and, thus, the microelectrode is likely
monitoring release events from only a few dopamine neurons. Moreover, these neurons can
vary widely in their propensity to fire in bursts217, the firing pattern that presumably
produces dopamine transients. As a result, some recording sites in the nucleus accumbens
produce high frequencies of dopamine transients, while others yield few or no transients
even when electrically-stimulated release is robust (indicating the proximity of functional
release sites)215. Nevertheless, when transients are detected, they are typically of similar
amplitude and duration regardless of the basal frequency (Figure 9).
8.3. Drug effects on rates of dopamine transients
Dopamine transients can be pharmacologically manipulated by drugs that directly or
indirectly target dopamine transmission. Drugs that block dopamine uptake, such as
nomifensine and cocaine, increase both the frequency and size of dopamine transients; the
amplitude and duration of transients are enhanced in a manner consistent with their effects
on electrically stimulated dopamine signals218–220. The cannabinoid agonist WIN55,212-2
also increases the frequency and amplitude of dopamine transients221, but via different
mechanisms: CB1 receptor activation by WIN55,212-2 on presynaptic GABA terminals in
the ventral tegmental area (a brain regions that contains cell bodies of dopamine neurons)
reduces GABA transmission and, thus, disinhibits postsynaptic dopamine cell bodies,
resulting in increased burst firing of dopamine neurons222,223. Similarly, nicotine boosts the
frequency and amplitude of dopamine transients224, which may be due to both enhanced
burst firing of dopamine neurons225 and enhanced calcium-dependent dopamine release at
the terminals226. In contrast, ethanol increases the frequency of dopamine transients only in
a subset of recording sites (“ethanol-responsive sites”)224.
In addition to detecting changes in transient frequency, FSCV has revealed short-term
changes in tonic dopamine levels following drug administration. Cocaine, nicotine, and
ethanol can all induce gradual increases in dopamine levels (over tens of seconds) on which
individual dopamine transients are superimposed218,224. With cocaine, these slower surges
of dopamine are dose-dependent218.
Not every site within the nucleus accumbens is equally sensitive to these various drugs. As
mentioned above, ethanol induces dopamine transients only at some recording sites within
the accumbens, with other sites yielding no clear change in transient rates224. The
heterogeneous effects of ethanol may reflect the sensitivity of subsets of dopamine neurons
to fire in bursts in response to this drug227–229. Site-specific variation has also been reported
for cocaine. Specifically, more transients are observed at release sites that already yield
dopamine transients, whereas in sites devoid of transients (but containing dopamine release
sites as evidenced by electrically stimulated release) no additional transients are induced by
cocaine215. This finding suggests that a major mechanism by which cocaine increases
transient frequency is to amplify ongoing dopamine transients as opposed to triggering the
occurrence of additional transients, consistent with cocaine’s primary effects at the terminal
rather than the cell body.
8.4. Dopamine transients during learning and reinforcement
A rich area of psychological research has focused on cognitive mechanisms of learning and
reinforcement230. Certain objects or experiences are rewarding or reinforcing, and animals
readily learn that environmental cues can signal future availability of rewards. In order to
make the association between the environmental cue, or conditioned stimulus (CS), and the
reward, or unconditioned stimulus (US), an element of surprise is necessary. In other words,
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learning occurs when the US is unexpected. In contrast, if the US is always predicted by a
CS (and the animal has learned this), no additional learning occurs. The predictability of the
US can be described as prediction error (λ – ΣV)231,232, in which λ is the maximum amount
of learning or prediction that can be achieved of the predictability of the US, and ΣV is the
sum of the amount of learning (or prediction) that actually occurred at a given presentation
of the US. Thus, when the US is completely unexpected, ΣV = 0 and the prediction error
equals λ. Conversely, when the US is fully expected, ΣV = λ and the prediction error is zero.
Is it possible that a single set of neurons could encode this prediction error in its activity?
Electrophysiological studies of dopamine neurons suggest that this is so206,232. For example,
the majority of dopamine neurons in the monkey midbrain show a brief increase in firing
rate at the unexpected presentation of a reward (ΣV = 0)233. Moreover, when the reward is
fully predicted by a CS (ΣV = λ), the dopamine cells no longer increase firing at the reward,
but rather at the presentation of the CS, which itself was unexpected233. Omission errors,
i.e., the unexpected omissions of rewards that were fully predicted by a CS, are also encoded
by dopamine neurons with an inhibition of firing at the time that the reward would have
occurred206,234. Finally, the excitation of dopamine neurons in response to both an
unexpected reward and a CS predicting a reward vary in intensity with the magnitude of the
actual or predicted reward3.
While the firing rates of dopamine neurons appear to encode prediction error for rewards, it
is not a certainty that dopamine release at the terminal follows suit. Local influences on
dopamine release185,235,236, as well as facilitation and depression mechanisms triggered by
recent action potentials201, can induce a mismatch between neuronal firing and dopamine
release237. Thus, fast electrochemical techniques are necessary to examine dopamine release
in specific terminal regions during learning and reinforcement.
The hypothesis of dopamine as a learning signal for reward first predicts that dopamine
release would occur at the unexpected presentation of reinforcing stimuli. Indeed, the
earliest measurements of dopamine transients were at the presentation of novel and
reinforcing stimuli211,213,214,219, a response that habituated as the presentations became
more predictable214.
A second prediction is that dopamine release would occur at the unexpected presentation of
stimuli that forecast a reward, i.e. a CS. To determine this, dopamine release in response to a
CS associated with cocaine was measured. Rats were trained to self-administer cocaine by
pressing a lever in an operant box. At each lever press, a multimodal stimulus (light, tone
and lever retraction) was activated along with the cocaine infusion. When dopamine was
monitored with FSCV, dopamine transients were observed time-locked to the lever press
(Figure 10), with the maximal concentration occurring 1.5 s after the press238. Was the
signal due to pressing the lever, a pharmacological effect of cocaine, or the presentation of
the cues? Several pieces of evidence support that the transient was associated with cues,
which were serving as a CS for cocaine. First, when the multimodal stimulus was presented
noncontingently (i.e., apart from the rat pressing the lever), a dopamine transient was
elicited238. Second, noncontingently-delivered cocaine in a group of untrained rats
demonstrated that dopamine transients induced by the pharmacological effects of cocaine
were only detected > 30 s after the lever press/infusion220. Finally, when rats underwent
extinction – that is, lever pressing elicited the multimodal stimulus but saline was delivered
instead of cocaine – the dopamine transients time-locked to the lever press were
dramatically attenuated239, as would be predicted by a diminished ΣV. Moreover, when
cocaine self-administration was reinstated in these rats (increasing ΣV), the dopamine
transients reappeared239.
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The plasticity of the dopamine learning signal was explicitly evaluated in a set of
experiments by Day and colleagues240. First, dopamine transients were detected at the
unexpected presentation of a sucrose reward (ΣV = 0), while a multimodal stimulus (light
and lever extension) that did not predict anything did not evoke changes in dopamine
concentration. In another group of rats, the multimodal stimulus (CS) had been repeatedly
paired with the sucrose reward for several days. In this case, dopamine transients were
detected at the presentation of the CS and not at the subsequent presentation of the sucrose
(ΣV = λ, Figure 11). This shift in dopamine signal from the primary reward to the CS after
learning confirms chemically what had previously been reported for dopamine cell
firing206,233. Finally, Day and colleagues240 examined the plasticity of the dopamine
response during the early learning of the CS-US association. Rats received 25 pairings of the
multimodal stimulus with sucrose. Dopamine transients occurred at the presentation of the
sucrose during all of the pairings (Figure 11), with the peak of the dopamine signal time-
locked to the retrieval of the sucrose pellet. In contrast, no changes in dopamine
concentration were observed at the presentation of the CS during early pairings (ΣV = 0),
but in 4 out of 6 rats, dopamine transients emerged at the presentation of the CS later in the
session, as learning occurred (as ΣV increased). Thus, these data provide evidence that
dopamine transients are involved in learning about rewards and actively adapt during the
learning process.
The hypothesis that fast dopamine signaling acts as a prediction error is focused on learning
about CS-US associations. What does the animal do with this prediction error? Broadly
speaking, dopamine transmission is thought to facilitate appetitive and seeking
behavior241,242. Thus, dopamine transients that are triggered by rewards or stimuli that
predict rewards could lead the animal to approach and consume the reward. Consistent with
this, when behaviors were examined in the seconds immediately preceding and following
dopamine transients during interaction with another rat, we found that while no particular
behavior was always associated with the signals, transients were likely to be followed by
approach behaviors to the other rat243. Further support comes from measurements of
dopamine release during operant responding for sucrose244. In this study, a multimodal cue
(light and lever extension) signaled sucrose availability. Remarkably, dopamine
concentrations began to rise at the presentation of the cue, then peaked when the rat
subsequently pressed the lever, suggesting that the dopamine transient induced by the CS
facilitated the drive to obtain the sucrose. These and other data238 suggest that dopamine
transients can facilitate reward-seeking behavior.
If dopamine transients act as learning signals and direct subsequent behavior, what happens
when phasic dopamine signaling becomes abnormal due to drugs or disease? In the case of a
drug addiction, such dysfunction would presumably lead to abnormal learning and
prediction errors that could underlie the pathological compulsion to seek and consume
drugs. Moreover, the dopamine signals at the unexpected presentation of environmental cues
previously associated with drug-taking may precipitate craving and relapse. Therefore, one
potential target for pharmacological treatment of addiction may be the phasic dopamine
signaling associated with addictive drugs. One potential therapeutic drug is rimonabant, a
cannabinoid CB1 antagonist. In a recent voltammetric study, many acute effects of cocaine,
nicotine and ethanol (including increased frequency of transients) were blocked by
pretreatment with rimonabant224. As many anti-addiction medications are hypothesized to
act on the positive reinforcing effects of drugs via the dopamine system, future research can
use electrochemical techniques to directly test these hypotheses.
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9. Electrophysiological tools to study the actions of neurotransmitters
Neuroscientists have developed a number of tools and approaches to study phenomena
associated with neurotransmission. These include methods to record the electrical activity of
neurons and methods to introduce minute amounts of chemical substances directly onto
neurons. These are reviewed here because they are readily combined with the
electrochemical sensors described in the previous sections. In addition, we review the
systems in which dopamine effects have been studied. These vary greatly in complexity, and
range from single cultured neurons to neurons in awake and behaving animals. Future
advances in the understanding of chemical neurotransmission will require the combined use
of these approaches.
9.1. Methods to measure the electrical activity of neurons
Electrophysiological methods sample the electrical properties of neurons and provide the
most rapid, direct measurement of the effect of a neurotransmitter upon a neuron.
Intracellular methods require inserting an electrode into a cell and monitoring the cellular
response to a perturbation. For example, a current can be applied to the cell membrane while
the electrode monitors subsequent changes in voltage. Excitatory and inhibitory potentials
are observed when ion channels open in response to receptor activation. Alternatively, a
specific voltage can be clamped across the membrane while the electrode measures current
changes, termed excitatory or inhibitory currents. Patch clamp electrophysiology involves
attaching a capillary to the membrane to form a high resistance seal at which current and
voltage clamp experiments are performed. When used with an array of well established ion
channel blockers, patch clamp can be used to measure the activity of a subset of ion
channels on a cell membrane. Such intracellular techniques are commonly used with cell
culture or slice experiments where the neurons are readily accessible to the experimenter,
but its use is feasible only in rare cases in an awake animal245.
For in vivo preparations, extracellular recordings are frequently performed where changes in
potential caused by ion flow from an action potential are measured at a distance from the
target neuron. The electrode is connected to a high impedance amplifier, and the transient
voltage signals resulting from neuronal firing are recorded. This technique is referred to as
single-unit recording. It is readily combined with cyclic voltammetry by the use of an
electronically controlled switch246. During voltammetry, the electrode is connected to a
current transducer, and during single-unit recording it is connected to a voltage measuring
amplifier. Single units can be detected with the electrode as far away as 50 µm from a
neuronal cell body247. The voltage changes that are measured are on the order of 50 µV and
have a duration of 1 – 2 ms. The voltages are measured versus a reference electrode and are
both high-and low-pass filtered to enhance signals in the 300–3000 Hz range.
9.2. Methods to introduce chemical agents
A variety of techniques allow introduction of selective chemical agents into the brain. The
major techniques are systemic administration, microinjection, reverse dialysis and
iontophoresis.
In systemic application, the compound is introduced to the entire preparation, either through
injection into the blood stream for animal preparations or introduction to the bath solution
for cell and slice preparations. Though relatively simple, systemic techniques have several
limitations, particularly in in vivo experiments. Many compounds cannot be administered in
this manner due to their inability to cross the blood-brain barrier. Moreover, the entire brain
is affected by the injection, potentially convoluting local results with changes up or
downstream in the neural circuitry. Finally, systemic applications are slow in comparison to
Robinson et al. Page 25













the transient nature of neuronal signaling, often requiring several minutes for onset to occur,
and hours or even days for complete clearance.
Microinjection is the administration of small volumes of a drug solution directly into a
specific brain region. Because this approach targets a subset of the brain and circumvents the
blood/brain barrier, microinjection offers many advantages over systemic application.
Microinjection has been used extensively by Gerhardt and coworkers to examine the rate of
disappearance of neurotransmitters248. A technique related to microinjection is reverse
dialysis with a microdialysis probe. A compound capable of crossing the dialysis membrane
is added to the buffer and diffuses from the probe into the sampling region. Both techniques
greatly improve the spatial resolution for drug application, but are still slow (occurring over
minutes) in comparison to rapid dopamine signaling.
Another approach, iontophoresis, is used to apply local concentrations of a compound with a
net ionic charge over a period of a few seconds using an applied current. While producing
locally large concentrations, iontophoresis only ejects small quantities of ions and, thus,
clearance by diffusion is rapid. The amount of a given compound ejected follows the
equation:
(19)
where the amount ejected in moles, M, is proportional to the ratio of the ejection current (i)
and ejection time (t) to the charge (z) and Faraday’s constant (F)249. This ratio is modified
by n, the ejection efficiency coefficient, which is empirically derived and varies significantly
between electrodes, thereby making the technique only quantitative if direct measurement of
ejection from each iontophoresis barrel is obtained250. For this reason, iontophoresis in most
applications is not quantitative.
Iontophoresis also suffers from several other disadvantages. The actual concentration ejected
is unknown and discriminating between a cell that is unresponsive to the manipulation and
an unsuccessful ejection is difficult251. Additionally, at large ejection currents iontophoresis
may electrically influence the activity of a neuron, independent of the pharmacological
action of the compound actually being ejected. This confound makes discrimination between
excitation and disinhibition is impossible252. However, pairing iontophoresis with a
detection technique such as cyclic voltammetry allows for concentrations and confirmation
of ejection to be obtained, circumventing some of the key disadvantages of the technique
(Figure 12). This was done some time ago246, but only recently has its use become more
common253.
9.3. Uses of chemical and electrical stimulation
All of the methods described in the preceding section can be used to stimulate neuronal
tissue either at the level of nerve, terminals, cell bodies, or both. The most general approach
is to use agents that directly depolarize the cell membrane such as elevated concentrations of
potassium ions or the excitatory amino acid n-methyl-d-aspartate (NMDA). Application of
K+ depolarizes the cell, forcing voltage-dependent ion channels to open and generate an
action potential. NMDA activates excitatory ionotropic glutamate receptors known as
NMDA receptors which depolarize the cell and generate an action potential.
Release of neurotransmitters is also commonly evoked by electrical stimulation as described
in Section 7.2. This method has several advantages over chemical methods. First, selectivity
can be obtained by stimulating specific neuronal pathways. Second, the stimulations can be
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brief, and third, there is no concern about diffusion of chemical reagents. However,
electrical stimulations force all neurons within the stimulated region to release
neurotransmitter simultaneously, which may not be an appropriate model for physiological
release events.
Because nerve terminals from a variety of neurons are interspersed, local stimulation will
generate release of several neurotransmitters. For this reason the results from chemical or
electrical stimulations at the cell body, termed remote stimulations, are often more easy to
interpret. As described in previous sections, remote stimulation of dopamine neurons in vivo
can produce short duration dopamine release events similar to physiological release events.
Because the stimulation occurs far from the terminal region, only neurons that project from
the stimulated region to the terminal field will release neurotransmitter. This gives remote
methods greater selectivity, although co-stimulation of other neurons may still occur.
One example of the non-selective nature of stimulations was obtained in a study of
electrically stimulated dopamine release254. Dopamine release was generated via electrical
stimulation of dopamine axons in the medial forebrain bundle, and both dopamine release
and changes in postsynaptic cell firing were simultaneously measured (Section 9.1).
Inhibitions and excitations of cell firing were recorded in response to the stimulation that
coincided with the lifetime of dopamine release. At recording sites of cells inhibited by the
stimulation, systemic injection of the vesicular monoamine transporter blocker RO4-1284
abolished dopamine release but not the postsynaptic inhibition. In contrast, systemic
administration of bicuculline, a GABAA antagonist, abolished the inhibition of cell firing.
These findings led to the conclusion that the inhibitions were caused by stimulating parallel
axons that release GABA in the nucleus accumbens, whereas electrically stimulated
dopamine release did not primarily impact the measured postsynaptic neuronal activity.
These findings reveal a deficiency in the specificity of electrical and chemical stimulation of
dopamine neurons that can obscure dopamine’s actions.
9.4. Neuronal preparations
The most common preparations for in vitro experiments are neuronal cell cultures. Cultured
neurons are ideal for the study of vesicular exocytosis, as the environment can be precisely
controlled, facilitating intracellular recording techniques. Neurons isolated in cultures
undergo adaptive changes and often form synapses with themselves, known as autapses. Co-
culture with glia and other neurons may improve the similarity to in vivo preparations.
Another commonly used approach is to use brain slices. In this preparation the results are
affected by the thickness and direction in which the brain is sliced. The slices need to be thin
(200–300 µm) to allow diffusion of glucose and oxygen into the inner regions of the slice.
Coronal slices are produced by taking a slice in the medial/lateral plane from the top to the
bottom of the brain. Coronal slices through brain regions supporting dopamine release do
not contain whole dopamine neurons, but only the dopamine terminals and their targets, the
cell bodies of medium spiny neurons. Nevertheless, the terminals still release dopamine
upon chemical or electrical stimulation. Sagittal and horizontal slices can contain whole
dopamine neurons along with medium spiny neurons; sagittal slices are vertical slices along
the entire length of the brain, and horizontal slices encompass the entire length of the brain
along the horizontal plane. However, all slice preparations differ from in vivo preparations
due to a lack of neurotransmitter tone and incomplete neural circuits that may confound the
results203.
Neurotransmission in the intact brain has been investigated in both anesthetized and freely
moving animals. Chloral hydrate and urethane are commonly used as anesthetics, and
chemical or electrical sensors are implanted into the brain regions of interest through small
holes in the skull. Atlases of rodent brain have been published, and they reference the
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location of different brain substructures relative to landmarks on the skull. During
experiments under anesthesia, the animal is usually placed in a stereotaxic apparatus which
holds the animal in place and allows the use of micromanipulators for precise positioning of
electrodes. However, anesthesia can cause drastic changes in neural activity255. Although
technically more difficult to perform, experiments in freely moving animals provide the
most physiologically relevant data as the neurons have experienced the least change from
normal conditions. For example, dopamine effects in these experiments occur within the
context of proper neurotransmitter tone, neural circuitry and firing rates. Moreover,
measurement in freely moving animals is the only method in which dopamine transmission
can be directly correlated to behavior.
The selections of recording technique, animal model, and drug delivery method control what
information regarding dopamine neurotransmission can be obtained. Each technique and
model introduces its own set of experimental confounds that must be considered in
interpretation of the results. Through analysis of the unique observations obtained from the
various recording techniques and animal models, a view of dopamine neurotransmission can
emerge.
10. Investigating dopamine’s actions on neurons
As described in earlier sections, the characteristics of the spontaneous release of dopamine
are being revealed, and the next step is to characterize the way in which dopamine interacts
with downstream neurons to affect behavior. This characterization requires a view of the
relevant biochemical signaling pathways including receptors and their influence on neuronal
activity.
10.1. Neurotransmitter receptors
The class of neurotransmitter receptors known as ionotropic receptors produces immediate
effects upon neurotransmitter binding because they function as voltage-gated ion channels.
Medium spiny neurons are the major target of dopamine release in the brain and have a
resting potential of around −85 mV. Increasing the conductance of sodium channels through
activation of ionotropic receptors shifts the membrane potential to more positive values and,
thus, may trigger an action potential. Conversely, other neurotransmitter receptors serve as
chloride channels which hyperpolarize the cell, thereby reducing the probability of action
potential generation. Opening calcium channels modulates neurotransmitter release, as well
as impacts protein phosphorylation within the cell. By measuring the conductances of these
specific receptor-linked channels and their effects on membrane potentials,
electrophysiologists can unravel the effects of neurotransmitters that interact with ionotropic
receptors.
In contrast, all identified dopamine receptors belong to the class of receptors known as G-
protein coupled receptors252. Unlike ionotropic receptors, the G-protein coupled receptors
are not directly linked to ion channels; instead, G-protein coupled receptors modulate
neuronal activity through interactions with a G-protein complex256. When activated by the
binding of a neurotransmitter, the α subunit dissociates from the γ, β complex and the
receptor. The α subunit then interacts with other proteins within the neuron, triggering
signaling cascades capable of producing a variety of effects from modulating ion channel
conductance to regulating protein expression. Activation of G-protein coupled receptors can
produce effects that last only milliseconds, or generate changes that persist for hours or
longer. Through a combination of electrophysiological and molecular biological
experiments, the complex effects of dopamine release are being characterized.
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Several dopamine receptors have been identified. The receptors currently known have been
placed into two primary groups based upon pharmacological characterization: the D1
family, which includes D1 and D5 receptors, and the D2 family, populated by D2, D3, and
D4 receptors. The D1, D2, and D3 receptors show high expression levels in the nucleus
accumbens257.
Dopamine receptors have been found to interact with potassium, sodium, and calcium
channels through adenylate cyclase, which converts ATP into the secondary messenger,
cAMP258. Investigations of the specific signaling cascades involving D1 and D2 receptors
have found that a key molecular target for postsynaptic dopamine receptor activation is the
protein DARPP-32. The DARPP-32 protein contains multiple phosphorylation sites.
Depending upon the sites phosphorylated, DARPP-32 is capable of interacting with various
protein phosphatases involved in cascades required for signal amplification and
integration259. Recent models employing current knowledge of signaling cascades from D1
receptor activation have shown that modulation of cAMP-dependent kinase and DARPP-32
persists for several hundred milliseconds longer than the duration of the receptor
activation260. Genetically modified mice that lack the DARPP-32 protein display a
decreased ability of dopamine to modulate ion channels and long-term neuronal activity261.
These knockout mice have also displayed attenuated behavioral responses to several drugs
of abuse, such as locomotion in response to cocaine or amphetamine administration261.
Because G-protein coupled receptor effects are mediated by second messengers, they occur
on a slower timescale than ionotropic receptor effects262. This delay is compounded by the
design of dopaminergic synapses in which dopamine receptors and transporters are located
both inside and outside of the synapse263. The net result is that dopamine must diffuse a
greater distance to reach its receptors in comparison to neurotransmitters such as glutamate
whose action is restricted to the synaptic cleft. The extra-synaptic action of dopamine has
led to the label “volume” transmitter, and dopamine release events are believed to affect
multiple targets186,264. A key example of dopamine’s delay was shown with observation of
two distinct responses to dopamine neuron stimulation in anesthetized rats265. A rapid-onset
excitation was followed by a second delayed excitation lasting several seconds after
electrical stimulation of the medial forebrain bundle. The initial excitation was due to co-
stimulation of glutamatergic neurons, while the delayed onset signal was found to be due to
dopamine release. The experiments estimated that dopamine receptor effects upon neuronal
activity have a delay of at least 200 ms from the release event until effects are observed265.
10.3. Presynaptic effects
Dopamine receptors are also located on the pre-synaptic terminals of dopamine neurons.
Through these receptors, termed autoreceptors, dopamine can modulate subsequent release
events (Section 7.2). Auto-inhibition of dopamine release is primarily mediated by D2
receptors. When dopamine is released, activation of pre-synaptic D2 receptors triggers an
intracellular cascade of events that leads to a decrease in calcium channel conductance and
down-regulation of tyrosine hydroxylase, an enzyme necessary for dopamine
synthesis266–269.
Experiments characterizing autoreceptor function have been performed in rat brain slices
and anesthetized rats using amperometry to detect dopamine release from a pair of electrical
stimulus trains with differing separations between each stimulation203,205,270. Comparison
of the relative maximum release from each stimulation allowed characterization of the
timescale of D2 receptor effects. The data described the modulation of dopamine release
with sub-second resolution over a time window of 200 ms to 5 s, with maximal inhibition at
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700ms in slices. In the anesthetized experiment, a maximal inhibition between 150–300 ms
after the stimulation was observed, with the effect disappearing within 600 ms. Moreover, as
described above (Section 7.2), these inhibitory effects of D2 receptor activation on
subsequent dopamine release desensitize over several seconds204.
Other neurotransmitters can also modulate release from dopaminergic nerve terminals.
Experiments in cultured neurons, slices, and anesthetized animals have shown that dopamine
release is strongly inhibited by increased glutamate levels271–273. Some controversy exists
over the glutamate receptor responsible for the inhibition, with both mGluR5 and a signaling
cascade involving AMPA receptors implicated235,236. The AMPA (alpha-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid) receptor cascade involves production of
hydrogen peroxide which then modulates potassium channel conductance, decreasing
dopamine release236. The mechanism involved in mGluR5-dependent inhibition has not yet
been explored. Nevertheless, the experiments are all evidence for the influence of tonic
glutamate levels upon dopamine release. Previous experiments have shown long-duration
(30 minutes) dopamine concentrations increases in response to stimulation of the basolateral
amygdala274,275. The increase in dopamine occurred with deactivation of the ventral
tegmental area suggesting that the basolateral amygdala stimulation was generating release
events at the terminals.
The modulation of dopamine release in the nucleus accumbens by nicotine, which activates
nicotinic acetylcholine receptors, has also been observed276,277. Like glutamate, the
application of nicotine inhibited dopamine release generated by a single release event.
However, in experiments designed similar to the paired-pulse experiments described earlier
involving D2 autoreceptors, nicotine was found to significantly increase the dopamine
release evoked by the second pulse. This finding suggests a potential mechanism for
acetylcholine’s role in reward-based learning and nicotine use by enhancing dopamine
release in response to repeated firing.
10.4. Postsynaptic effects
Dopamine is released onto medium spiny neurons throughout the striatum. These neurons
also receive glutamatergic input originating from the hippocampus, amygdala, prefrontal
cortex and thalamus263,278. The current hypothesis for the role of dopamine is that it gates
these incoming glutamatergic signals279. Specifically, dopamine is postulated to act as a
filter to increase the “signal-to-noise” of a given target neuron’s activity280. The local
anatomy within the NAc supports this model, as dopamine terminals converge onto necks of
dendritic spines and glutamatergic terminals project onto heads of the spines (Figure 13). As
discussed previously, the extrasynaptic placement of dopamine receptors, coupled with
volume transmission, allows dopamine to act across numerous targets. Dopamine release
would therefore saturate the region surrounding the release site with relatively slow onset
and offset and modulate the neuron’s response to glutamatergic inputs.
Intracellular electrophysiological recordings in anesthetized rats have shown the existence of
up and down states in medium spiny neurons281. The medium spiny neurons are dormant in
the more negative down state at approximately −85 mV, but they depolarize to
approximately −55 mV when entering the up state. Once in the up state, the neuron more
readily generates action potentials in response to glutamatergic inputs. The driving force
behind neurons entering the up state appears to be glutamate282. Dopamine finely tunes
neuronal activity within the states by means of opposing effects from D1 and D2
receptors283. The activation of D1 receptors increases the conductance of L-type calcium
channels and NMDA receptors, which stabilize the neuron in the up state284–286, leading to
enhanced excitability of the medium spiny neurons. Alternatively, activation of postsynaptic
D2 receptors reduces the conductance of calcium channels and excitatory AMPA receptors,
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thereby reducing medium spiny neuron excitability285,287. Recent experiments245 using
intracellular recordings in awake rats found that medium spiny neurons displayed the
predicted two-state behavior observed in slice preparations and anesthetized or asleep rats.
However, the neurons exhibited only a single state – the up state – when rats were awake.
This result calls into question the relevance of the up- and down-state hypothesis to interpret
neural activity during behavior.
Extracellular recordings (which are unable to distinguish up and down states) in anesthetized
and freely moving animals have primarily shown postsynaptic inhibitions in response to
dopamine in spontaneously active and glutamate-excited cells258. Dopamine and
amphetamine ejection via iontophoresis produced inhibitions that were blocked by both D1
and D2 antagonists288. However, stimulation of dopamine neurons has also been shown to
produce notable excitatory effects from dopamine release. Postsynaptic excitations induced
by NMDA injection into the medial forebrain bundle (which generates dopamine release)
lasted for 1 s after the stimulation and were sensitive to D1 receptor activation and
antagonism289.
Another example of the differential nature of dopamine’s effects was observed in a study by
Williams and Millar. These authors used voltammetric recordings to correlate dopamine
release evoked by various electrical stimulus trains with changes in medium spiny neuron
activity247. Medium spiny neurons displayed an increase in neuronal firing rate in response
to nanomolar concentrations of dopamine release, but a decrease following release events
producing more than 1 µM dopamine. Both responses to dopamine were abolished by
administration of alpha-methyl-p-tyrosine, which blocks dopamine synthesis and, thus,
abolishes vesicular dopamine release. The experiment was later successfully replicated using
introduction of dopamine via iontophoresis290. Although both D1 and D2 receptors were
speculated to be responsible for these effects, pharmacological verification was not
attempted.
The complex effects of dopamine on medium spiny neurons was elegantly explored in
experiments by Sulzer and colleagues that addressed the convergence of dopamine and
glutamate onto medium spiny neurons291. In the mouse slice, vesicular glutamate release
was visualized with 2-photon microscopy, dopamine release was monitored with
amperometry and FSCV, and postsynaptic changes in current were measured with whole-
cell patch clamp recordings. These experiments revealed that, in addition to any direct
effects on medium spiny neurons, dopamine modulated glutamate release onto these same
neurons via D2 receptors. Interestingly, while the most active glutamatergic terminals
appeared unaffected by D2 receptor activation, the other terminals were inhibited.
Furthermore, dopamine input performed as a low pass filter, as the D2-mediated inhibition
targeted glutamatergic terminals that had a low probability of release (i.e., released vesicles
more slowly) and that were firing at high frequencies (≥ 10 Hz). Therefore, by filtering less
active glutamatergic inputs to the medium spiny neurons, dopamine amplifies only the most
vigorous inputs.
Although the above experiments provide supporting evidence to elucidate the physiological
actions of dopamine, they do not reveal the function of dopamine in mediating complex
behavior tasks. For this goal, the spontaneous release of dopamine must be measured in real
time and correlated to cell firing in freely moving animals. This was recently accomplished
by using FSCV and electrophysiology at the same carbon-fiber electrode in rats253. The rats
were trained to press a lever to receive a small stimulation train into the ventral tegmental
area (i.e., intracranial self-stimulation), while neural activity was monitored in a subregion
of the nucleus accumbens called the shell. Dopamine release was evoked in the nucleus
accumbens by the electrical stimulation, but correlating dopamine release and neuronal cell
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firing at the stimulation would incur confounds observed in previous studies254 (see Section
9.3). Instead, naturally occurring dopamine release was correlated to cell firing. To reliably
elicit a dopamine transient, a compound cue (tone and light) preceded the opportunity to
press the lever by one second. As this cue consistently predicted the lever (ΣV = λ),
dopamine release was observed at the presentation of the cue (Figure 14). In addition, firing
rates of the majority of medium spiny neurons examined significantly changed at the
presentation of the cue as well. The most common response was an inhibition of firing
(Figure 15), and the second most frequent response was an excitation in firing rate at the
cue. Moreover, at almost 90% of the recording sites of these responsive medium spiny
neurons, dopamine transients were observed as well. In contrast, at recording sites where
neurons exhibited no change in firing at the cue, dopamine transients were typically absent,
despite the presence of electrically evoked dopamine release (indicating the proximity of
functional dopamine terminals). These data clearly demonstrate a correlation between
naturally occurring dopamine transients and changes in postsynaptic firing rate254.
Pharmacological manipulations were further used to explore the functional role of these
neural signals. First, dopamine receptor antagonists were microinjected into the accumbens
shell and opposing D1/D2 effects were observed. While the D1 receptor antagonist blocked
intracranial self-stimulation behavior at doses that did not affect general locomotion, a D2
receptor antagonist had no effect on intracranial self-stimulation behavior despite decreased
locomotor activity. Second, dopamine receptor antagonists were iontophoretically applied to
the accumbens shell adjacent to the carbon-fiber electrode to observe effects on firing
patterns of medium spiny neurons. While the D2 receptor antagonist had no effect on cell
firing, the D1 antagonist dramatically reduced both discrete inhibitions at the cue as well as
overall firing rate. Although dopamine transients were not measured during iontophoretic
application of the drugs, these data demonstrate that the association between dopamine
transients and short-term changes in firing of medium spiny neurons is mediated by D1
receptors254.
10.5. Other neurotransmitters
Emerging evidence suggests that dopamine terminals may co-release glutamate in addition
to dopamine. Currently, the expression of one type of vesicular glutamate transporter, the
VGlut2, has been shown in neurons that stain positive for tyrosine hydroxylase292,293. The
transporter is only expressed in a subset of DA neurons, and the majority of synapses
formed by these neurons do not display morphology typical of glutamatergic synapses294.
Robust expression of VGlut3, another vesicular glutamate transporter, has been shown in the
striatum and accumbens295. The expression of another glutamate transporter, VGlut3, in
serotonin, acetylcholine, and GABA neurons has been observed in other brain regions,
though not in tyrosine hydroxylase-positive neurons at this time295,296.
Indirect electrophysiological evidence exists in cultured neurons and slices to support co-
release of dopamine and glutamate. Investigation of dopamine neuron autapses, which are
formed when a neuron forms a synapse with itself in culture, demonstrated excitatory
postsynaptic potentials that were blocked by NMDA receptor antagonists in addition to
dopamine receptor antagonists297. In brain slices, rapid and delayed-onset excitatory
postsynaptic currents have been observed in response to dopamine neuron stimulation. In
this experiment only the rapid onset signal was sensitive to an AMPA glutamate receptor
antagonist298, indicating that this signal component resulted from glutamate release.
Correcting for potential confounds such as co-release of other neurotransmitters requires full
pharmacological analysis of post-synaptic effects. Thus, it is important to note that some
studies, such as those by Gonon on the time course of postsynaptic effects of dopamine265
(see Section 10.2), may have been confounded by co-release of glutamate.
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The possibility of co-release of glutamate and dopamine provides a future challenge for
investigators using in vivo chemical sensors of neurotransmitters. Simultaneous
measurements of glutamate and dopamine with a combined microprobe, such as the
multisided electrodes fabricated by Gerhardt89, could answer this question directly.
11. Investigating rapid changes in amino acid neurotransmitters
The electrochemically based sensors described in Section 6.2 are just beginning to be used
in neurochemical applications. Their future use in behavioral experiments will undoubtedly
lead to an increased understanding of their roles in behavior as is being discovered for
dopamine. However, rapid microdialysis methods for amino acids have already reached a
stage in development where they are providing important information on fast
neurotransmitter changes during behavior. These approaches employ a conventional
microdialysis probe but couple it online to a rapid separation system. This approach allows
immediate analysis with complete separation times of less than a minute.
11.1. Rapid analysis of amines by capillary electrophoresis
To achieve fast sampling and analysis, rapid microdialysis systems employ online
derivatization coupled with a gating approach that allows injection onto a fast separation
scheme. For fluorescence analysis, two derivatizing agents have been employed.
Naphthalene-2,3-dicarboxaldehyde has been used for the derivatization of dopamine and
amino acids299, and o-phthaldiadehyde has been used for derivatization of amines and
amino acids300. The advantage of both of these reagents is that they do not fluoresce before
derivatization but produce highly fluorescent derivatives of the neurotransmitter candidates.
Following gated introduction into a capillary, the compounds are separated by capillary
electrophoresis and detected by their fluorescence. Capillary electrophoresis requires low
sample volumes, and so it is ideal for this application. Laser-induced fluorescence provides
sensitivity in the attomole range. For amino acid separations, the separation can be repeated
every 14 s, leading to high sample throughput and high temporal resolution to monitor
chemical changes of neurotransmitters. With careful calibration of the dead time of the
system, the timing of behavioral events can be associated with neurochemical changes.
While the temporal resolution is not as high as with electrochemical sensors, the real
advantage is that multiple compounds can be followed. Indeed, in one recent example, 62
distinct compounds could be monitored in less that one minute301.
11.2. Neurochemical studies with rapid microdialysis
Early applications of rapid microdialysis employed pharmacological agents299 or
depolarization with high K+ solutions. For example, 60 mM K+ was found to elevate
glutamate, GABA, and taurine in the retina of the isolated larval salamander302. Similarly, D-
serine release evoked by high K+ in the rat striatum was monitored with 12.5 s resolution303.
The time course of elevation of dopamine in the rat striatum following cocaine injection was
followed with 2 minute resolution304. The entire time course could be followed for 16 min.
In contrast, when dopamine was sampled by FSCV in a similar experiment, the tonic
dopamine response to cocaine could only be followed for 2 min because of the inherent drift
in the voltammetry experiment218. These two different approaches to the same experiment
demonstrate the strengths and limitations of each technique.
Rapid microdialysis has been adapted for use in freely moving rats. This allows
neurotransmitters to be monitored during behavior. Neurotransmitters were evaluated in the
rat nucleus accumbens during exposure to the predator fox odor, 2, 5-dihydro-2,4,5-
trimethylthiazoline305. Such odors elicit defensive behavioral responses in rats, such as
increases in locomotion and burrowing. In rats that exhibited such behavior, enhanced
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concentrations of glutamate and GABA were observed. However, animals that did not show
such behavioral responses did not have a change in their striatal amino acid levels. The high
temporal resolution revealed that the neurochemical changes were secondary to the
behavioral changes. Thus, the neurochemical changes may have reflected the state of fear in
the animal during exposure to the odorant.
Amino acids neurotransmitters have been measured during conditioned fear26 in the
amygdala, a brain area important for fearful emotion and memory. In this experiment, one
set of rats were subjected to foot shock (US), while another group was exposed to a noise
(CS) that preceded foot shock. During training, rapid and transient glutamate and GABA
concentration increases were observed during the first pairing of the CS and US. In contrast,
rats receiving unsignaled shock showed few changes at first, but with continued shocks
glutamate tended to increase. These chemical changes occurred on a subminute time scale
and would have been difficult to distinguish with slower sampling.
11.3. Current advances in rapid microdialysis
As the previous examples show, rapid microdialysis is a very powerful technique that
provides multicomponent analyses on a time scale that is compatible with many
neurochemical processes. However, assembling and miniaturizing all of the necessary
components has restricted its use. Two approaches are directed at making its use more
commonplace. First is the use of microfluidic chips to allow the derivatization, gated
introduction, separation and detection all on one chip306. Early developments in this regard
show that sensitivity can be maintained while the operation is simplified and automated. The
second development is the use of minitiarized sampling devices that lessen the damage to
tissue caused by the microdialysis probes in use today307,308. These developments will
expand the use of this promising technique.
12. Conclusions
Investigating the role of neurotransmitters on neural activity and animal behavior is a
complex task, but improvement of detection techniques makes real-time measurement of
physiological concentrations of some neurotransmitters in the brain possible. To form a
complete view of chemical neurotransmission, the interaction between factors modulating
release, post-synaptic firing rates, and intracellular signaling need to be investigated. A
wealth of information regarding the actions of dopamine in cultured cells, brain slices, and
anesthetized animals has been produced to date. A current advance is correlation of real-
time presynaptic dopamine release events with postsynaptic cell firing in awake, behaving
animals. In such a complex system, the potential for non-dopaminergic effects convoluting
the interpretation of results is high. Thus, it will be important to pair the recording
techniques with local drug delivery systems such as iontophoresis to confirm dopamine’s
actions. Although the technology is currently in place to achieve this goal for dopamine
neurotransmission, the development of newer sensors will enable this concept to be
extended to a larger number of neurotransmitters. Future directions for innovation include
sensor arrays, electrodes that can be chronically implanted, and the combined use of sensors
and other traditional approaches to gain a more complete understanding of chemical
neurotransmission.
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AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; a glutamate analog
that activates the ionotropic AMPA receptor for glutamate
CS Conditioned stimulus; a previously neutral stimulus that gains significance as it
is repeatedly paired with an unconditioned stimulus
DOPAC 3,4 dihydroxyphenylacetic acid
fMRI Functional magnetic resonance imaging; a spectroscopic technique
FSCV Fast-scan cyclic voltammetry
GABA γ-aminobutyric acid
L-DOPA 3,4-dihydroxyphenylalanine
NMDA N-methyl-d-aspartate; an amino acid derivative that activates the ionotropic
NMDA receptor for glutamate
PET Positron emission tomography; a spectroscopic technique
US Unconditioned stimulus; a stimulus that evokes an innate response, such as a
food or drug reward
λ – ΣV prediction error in learning model, with λ as the maximum amount of learning
or prediction that can be achieved of the predictability of the US, and ΣV as the
sum of the amount of learning (or prediction) that actually occurred at a given
presentation of the US
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Data taken from Knutson et al., 200328 showing blood oxygen-level-dependent signals
recorded from a human subject playing a neuroeconomic game. Note that the region
highlighted in the panel labeled anticipated gain is the nucleus accumbens, a region that uses
dopamine as a neurotransmitter. Reprinted with permission; copyright 2003, Elsevier.
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Diagram of fast scan cyclic voltammetry of dopamine. A range of potentials such as the
triangle waveform (top left) is applied to the carbon-fiber microelectrode (center). During
the anodic scan dopamine oxidizes, and on the cathodic scan dopamine-o-quinone reduces.
The resulting current is measured as a cyclic voltammogram; the voltammogram shown here
(right) is background-subtracted to reveal the current due to dopamine oxidation and
reduction. Reprinted with permission from311. Copyright 2003, Elsevier.
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Principles underlying enymatic, amperometric microelectrode biosensors. (a) A
microelectrode biosensor will generally have a rigid insulating body with a pin at one end
for connection to the potentiostat and the fine sensing tip at the other. A Pt wire connected to
the pin emerges from the tip of the body to give a defined sensing area. The sensing area is
then coated with a special layer, which at the very minimum comprises the enzymatic layer.
In some designs, there can be inner and outer selectively permeable layers to exclude
electroactive interferences and reduce fouling of the sensor. (b) Examples of two enzymatic
cascades used to measure signaling by glutamate and acetylcholine in the brain. Note that
the analyte is converted into an electrochemically active product – in this case H2O2 – that
can be detected by the microelectrode. (c) The analyte of interest diffuses into the enzymatic
layer and is catalyzed by the enzymes to peroxide; this then diffuses to the electrode surface
through any inner selectively permeable layers. However, interferences can be rejected
either by an outer layer, such as cellulose acetate, or by an inner layer, such as Nafion.
Adapted from reference176 with permission. Copyright 2005, Elsevier.
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Pressure ejection of dopamine into the slice as detected with an adjacent voltammetric
electrode. The tip of the pipette was secured at a 70 µm distance from the working electrode.
First, dopamine was ejected from a pipette into the cortex. The entire assembly was then
raised and lowered into the caudate nucleus and the ejection repeated. Dopamine was only
observed in the caudate nucleus after the slice had been perfused with 10 µM nomifensine, a
dopamine uptake blocker. Reprinted with permission from181. Copyright 1989 Elsevier.
Robinson et al. Page 49














Three-dimensional plots of concentration as function of distance and time for three different
uptake conditions. All calculations were based on a numerical solution of Fick’s second law
coupled to the Michaelis-Menten equation. Iontophoresis lasted for the first 10 s. The upper
graph was computed with Vmax = 0.2, uM s−1, Km = 0.15 µM, i.e., standard Michaelis-
Menten parameters. The middle graph was computed with Vmax = 0.2, uM s−1, Km = 6.0
µM, i.e., as if uptake was inhibited by an agent like nomifensine. The bottom graph was
computed with Vmax = 0, i.e., with no uptake. Reprinted with permission from184. Copyright
1995 Biophysical Society
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Effects of increasing concentrations of cocaine on one-pulse stimulated dopamine efflux in a
single brain slice containing the caudate nucleus. Data was collected in a single electrode
placement area of the slice by using a cumulative dosing regimen. Increasing doses were
added at 30-min intervals at the concentrations indicated. Arrow, the time when the stimulus
pulse was applied. Symbols are data points, collected every 100 ms, and lines connect the
symbols for clarity. INSET: disappearance of dopamine after stimulation. Data was time-
shifted so that the initial dopamine concentration was 1 µM for each plot. Reprinted with
permission from312. Copyright 1995 American Society for Pharmacology and Experimental
Therapeutics.
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Dynamic model reveals multiple adaptive mechanisms for ongoing dopamine release. A,
Semi-log plot of the normalized error for fitting the model to experimental data versus the
number of independent dynamic components Ij. Representative fits are shown from four
representative animals. The error decreases up to three components and does not improve
appreciably beyond that. B, The three dynamic components consistently captured by the
model: short-lasting facilitation (top), short-lasting depression (middle), and longer-lasting
depression (bottom). These time-dependent mathematical components are induced by each
action potential (arrow) and multiplicatively modify the amplitude of dopamine release for
future action potentials. C, Fit of dynamic model to dopamine released during a single
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repetitive electrical stimulation (24 pulses, 60 Hz, 120 µA) applied to dopamine neurons of
an ambulant rat. In all panels, the model is grey, data are black, and r2 is the correlation
coefficient. D, Fit of model to dopamine fluctuations evoked in an anesthetized animal by
more intense stimulus trains. Each repetitive stimulus (vertical bar) consisted of 600 pulses
(60 Hz, 120 µA). The repetitive stimulus trains were delivered at 2, 5, 10, or 20 min
intervals. Depression is present that is still evident on the next stimulus with 2 min
interstimulus intervals. At longer intervals there is greater recovery of release. Inset,
Response for a single 600 pulse train (60 Hz, 120 µA). E, Fit of model to dopamine
fluctuations evoked by stimuli as in C repeated at 2 sec intervals. Facilitation is apparent. F,
Stimuli as in C repeated at 5 sec intervals. A gradual depression is apparent. Reprinted with
permission from201. Copyright 2004 Society for Neuroscience.
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Two dopamine concentration transients in the olfactory tubercule of a male rat associated
with the introduction of a receptive female to the test chamber and subsequent contact. A, A
4-sec trace of the electrochemical signal at the oxidation potential of dopamine (0.6 V versus
Ag/AgCl reference) converted to dopamine concentration using the in vitro calibration of
the electrode after the experiment. The electrochemical scans confirmed to be dopamine by
the cyclic voltammograms are indicated by open circles. B, Cyclic voltammograms
corresponding to the electrochemical signal at the times indicated by the arrows. The cyclic
voltammograms verify that the changes in electrochemical signal during the two transients
are attributable to the oxidation of dopamine (middle and right), whereas no changes in
dopamine are apparent beforehand (left). The oxidative and reductive peaks of the dopamine
transients are compared with those of dopamine obtained during the electrical stimulation of
the dopamine fibers (dotted line, scaled to size). C, The video record of the experiment
corresponding to the electrochemical signal at the times indicated by the arrows. The first
dopamine transient coincided with the entrance of the female to the test chamber and was
followed by immediate orientation of the male toward the female. The second transient was
concurrent with the initial whisker contact between the rats and was followed by
investigative sniffing of the female by the male. Reprinted with permission from214.
Copyright 2002 Society for Neuroscience.
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Representative recordings of dopamine transients in a site in the nucleus accumbens
supporting few dopamine transients (A) and in one supporting frequent transients (B),
recorded in separate rats. The color plot132 (bottom) illustrates changes in current (color) by
applied potential (y-axis) over a 10-s window (x-axis). Changes in current at the oxidation
potential of dopamine, indicated on the color plot by the white dotted line, are shown in the
trace above the color plot. Increases in current confirmed to be due to dopamine oxidation
(dopamine transients) are designated by the asterisks. Cyclic voltammograms of selected
dopamine transients (solid lines) are shown above the traces, along with electrically
stimulated dopamine signals from the same site (scaled to the dopamine transient, dotted
lines).
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Dopamine transients during cocaine self-administration. Left panel: dopamine increases
before the lever press (time 0, solid line) and immediately after. Right panel: the cyclic
voltammogram indicates the substance detected was dopamine. The solid line is the cyclic
voltammogram taken at the peak of the dopamine response, and the dashed line is the cyclic
voltammogram taken during electrical stimulation of the ventral tegmental area (24 pulses,
125 µA, at 60 Hz) normalized to the peak amplitude for the response at the lever press.
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Voltammetric responses during a behavioral task measured in the rat nucleus accumbens. At
time 0 in both panels a lever was extended and it was retracted after 10s (blue bar).
Subsequently a sucrose pellet was dispensed. A. Results from a single animal on the first
day. Note the dopamine transient occurs with sucrose retrieval. B. After 10 days of training
the dopamine transient occurs with the lever extension, the cue that predicts the later
delivery of sucrose. Adapted from reference240.
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Carbon-fiber electrode fabricated with three barrels for iontophoresis. Note the filament
within the capillaries—this acts as a wick to aid in filling the barrels.
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Influences of dopamine release on typical medium spiny neurons in the dorsal and ventral
striatum. Dopamine released by impulses from synaptic varicosities activates a few synaptic
receptors (probably of D2 type in the low-affinity state) and diffuses rapidly out of the
synapse to reach low affinity D1 type receptors that are located nearby, within corticostriatal
synapses, or at a limited distance. Phasically increased dopamine activates nearby high-
affinity D2 type receptors to saturation. D2 receptors remain partly activated by the ambient
dopamine concentrations after the phasically increased release. Extrasynaptically released
dopamine may get diluted by diffusion and activate high-affinity D2 receptors. It should be
noted that, in variance with this schematic diagram, most D1 and D2 receptors are located
on different neurons. Glutamate released from corticostriatal terminals reaches postsynaptic
receptors located on the same dendritic spines as dopamine varicosities. Glutamate also
reaches presynaptic dopamine varicosities where it controls dopamine release. Dopamine
influences on spiny neurons in frontal cortex are comparable in many respects. Reprinted
with permission from reference313. Copyright 1998 American Physiological Society.
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Dopamine responses during intracranial self-stimulation. A. Timing diagram for lever
extension, audiovisual cue, and electrical stimulation. B. Dopamine responses measured by
cyclic voltammetry and extracted with principal component regression. Reprinted with
permission from reference253. Copyright 2007 Elsevier.
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Simultaneous measurement of firing patterns of neurons in the nucleus accumbens with
subsecond dopamine changes measured at the same electrode during intracranial self
stimulation. The perievent histogram was obtained by summing single unit events recorded
from a single neuron over individual trials. The overlaid trace (red) show the time course of
single-session extracellular dopamine concentration changes simultaneously measured at the
same loci where neurons were recorded. Cue onset, green symbols; lever extension, black
symbols; lever press, blue crosses, lever press; red dots are the stimulus delivery. The arrow
indicates where unit activity and dopamine simultaneously change. Adapted from253 with
permission. Copyright 2007 Elsevier.
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Table 1














Homovanilic Acid +0.5 V
3-Methoxytyramine +0.5 V
Tryptophan derivatives +0.8 V
Serotonin +0.35 V

























Ascorbic Acid +0.2 V
Uric acid309 +0.3 V
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